



APPENDICES

annexes

ANNUAL REPORT 2017
Rapport annuel 2017

INTERNATIONAL PUBLICATIONS

Gustave Roussy 2017 with an impact factor between 5 and 10
(except meetings/poster abstracts)

PUBLICATIONS INTERNATIONALES

Gustave Roussy 2017 avec impact factor
5 à 10 (hors meeting/poster abstracts)

Abate F., da Silva-Almeida A.C., Zairis S., Robles-Valero J., Couronne L., Khiabani H., Quinn S.A., Kim M.Y., Laginestra M.A., Kim C., Fiore D., Bhagat G., Piris M.A., Campo E., Lossos I.S., Bernard O.A., Inghirami G., Pileri S., Bustelo X.R., Rabadan R., Ferrando A.A., and Palomero T. Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. [2017] Proceedings of the National Academy of Sciences of the United States of America (114) 4 : 764-769. Impact factor : 9.504

Adam R., Yi B., Innominato P.F., Barroso E., Laurent C., Giuliante F., Capussotti L., Lapointe R., Regimbeau J.M., Lopez-Ben S., Isoniemi H., Hubert C., Lin J.K., Gruenberger T., Elias D., Skipenko O.G., and Guglielmi A. Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients. [2017] European Journal of Cancer (78) : 7-15. Impact factor : 7.191

Aleksandrova K., Jenab M., Leitzmann M., Bueno-de-Mesquita B., Kaaks R., Trichopoulos A., Bamia C., Lagiou P., Rinaldi S., Freisling H., Carayol M., Pischon T., Drogan D., Weiderpass E., Jakzyn P., Overvad K., Dahm C.C., Tjonneland A., Boutron-Ruault M.C., Kuhn T., Peppia E., Valanou E., La Vecchia C., Palli D., Panico S., Sacerdote C., Agnoli C., Tumino R., May A., van Vulpen J., Benjaminsen B.K., Oluwafemi O.S., Quiros J.R., Bonet C., Sanchez M.J., Dorransoro M., Navarro C., Barricarte A., van Guelpen B., Wennberg P., Key T.J., Khaw K.T., Wareham N., Assi N., Ward H.A., Aune D., Riboli E., and Boeing H. Physical activity, mediating factors and risk of colon cancer: insights into adiposity and circulating biomarkers from the EPIC cohort. [2017] International journal of epidemiology (46) 6 : 1823-1835. Impact factor : 8.360

Allard M.A., Adam R., Giuliante F., Lapointe R., Hubert C., Ijzermans J.N.M., Mirza D.F., Elias D., Laurent C., Gruenberger T., Poston G., Letoublon C., Isoniemi H., Lucidi V., Popescu I., and Figueras J. Long-term outcomes of patients with 10 or more colorectal liver metastases. [2017] British Journal of Cancer (117) 5 : 604-611. Impact factor : 5.922

Ambatipudi S., Horvath S., Perrier F., Cuenin C., Hernandez-Vargas H., Le Calvez-Kelm F., Durand G., Byrnes G., Ferrari P.,

Bouaoun L., Sklias A., Chajes V., Overvad K., Severi G., Baglietto L., Clavel-Chapelon F., Kaaks R., Barrdahl M., Boeing H., Trichopoulos A., Lagiou P., Naska A., Masala G., Agnoli C., Polidoro S., Tumino R., Panico S., Dolle M., Peeters P.H.M., Onland-Moret N.C., Sandanger T.M., Nost T.H., Weiderpass Vainio E., Quiros J.R., Agudo A., Rodriguez-Barranco M., Huerta Castano J.M., Barricarte A., Fernandez A.M., Travis R.C., Vineis P., Muller D.C., Riboli E., Gunter M., Romieu I., and Herceg Z. DNA methylome analysis identifies accelerated epigenetic ageing associated with postmenopausal breast cancer susceptibility. [2017] European Journal of Cancer (75) : 299-307. Impact factor : 7.191

Andersen Z.J., Stafoggia M., Weinmayr G., Pedersen M., Galassi C., Jorgensen J.T., Oudin A., Forsberg B., Olsson D., Oftedal B., Aasvang G.M., Aamodt G., Pyko A., Pershagen G., Korek M., De Faire U., Pedersen N.L., Ostenson C.G., Fratiglioni L., Eriksen K.T., Tjonneland A., Peeters P.H., Bueno-de-Mesquita B., Plusquin M., Key T.J., Jaensch A., Nagel G., Lang A., Wang M., Tsai M.Y., Fournier A., Boutron-Ruault M.C., Baglietto L., Grioni S., Marcon A., Krogh V., Ricceri F., Sacerdote C., Migliore E., Tamayo-Uria I., Amiano P., Dorransoro M., Vermeulen R., Sokhi R., Keuken M., de Hoogh K., Beelen R., Vineis P., Cesaroni G., Brunekreef B., Hoek G., and Raaschou-Nielsen O. Long-term exposure to ambient air pollution and incidence of postmenopausal breast cancer in 15 European cohorts within the ESCAPE project. [2017] Environmental Health Perspectives (125) 10 : 107005. Impact factor : 8.309

Angevin E., Spitaleri G., Rodon J., Dotti K., Isambert N., Salvagni S., Moreno V., Assadourian S., Gomez C., Harnois M., Hollebecque A., Azaro A., Hervieu A., Rihawi K., and De Marinis F. A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification. [2017] European Journal of Cancer (87) : 131-139. Impact factor : 7.191

Angevin E., Isambert N., Trillet-Lenoir V., You B., Alexandre J., Zalcman G., Vielh P., Farace F., Valleix F., Podoll T., Kuramochi Y., Miyashita I., Hosono O., Dang N.H., Ohnuma K., Yamada T., Kaneko Y., and Morimoto C. First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers. [2017] British Journal of Cancer (116) 9 : 1126-1134. Impact factor : 5.922

Angevin E., Cassier P.A., Italiano A., Goncalves A., Gazzah A., Terret C., Toulmonde M., Gravis G., Varga A., Parlavacchio C., Paci A., Poinson V., Soria J.C., Drubay D., and Hollebecque A. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. [2017] European Journal of Cancer (83) : 194-202. Impact factor : 7.191

Annede P., Gouy S., Mazon R., Bentivegna E., Maroun P., Petit C., Dumas I., Leary A., Genestie C., Lhomme C., Deutsch E., Morice P., Pautier P., Haie-Meder C., and Chargari C. Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment. [2017] Oncologist (22) 2 : 182-188. Impact factor : 5.306

Armstrong A.J., Saad F., Phung, Dmuchowski C., Shore N.D., Fizazi K., Hirmand M., Forer D., Scher H.I., and Bono J. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. [2017] Cancer (123) 12 : 2303-2311. Impact factor : 6.537

Aspeshlagh S., Matias M., Palomar V., Derclé L., Lanoy E., Soria J.C., and Postel-Vinay S. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? [2017] European Journal of Cancer (87) : 65-74. Impact factor : 7.191

Attieh Y., Clark A.G., Grass C., Richon S., Pocard M., Mariani P., Elkhatib N., Betz T., Gurchenkov B., and Vignjevic D.M. Cancer-associated fibroblasts lead tumor invasion through integrin-beta3-dependent fibronectin assembly. [2017] Journal of Cell Biology (216) 11 : 3509-3520. Impact factor : 8.784

Azan A., Untereiner V., Descamps L., Merla C., Gobinet C., Breton M., Piot O., and Mir L.M. Comprehensive Characterization of the Interaction between Pulsed Electric Fields and Live Cells by Confocal Raman Microspectroscopy. [2017] Analytical chemistry (89) 20 : 10790-10797. Impact factor : 6.042

- Azan A., Caspers P.J., Bakker Schut T.C., Roy S., Boutros C., Mateus C., Routier E., Besse B., Planchard D., Seck A., Kamsu-Kom N., Tomasic G., Koljenovic S., Noordhoek H., V, Matthieu T., Lanoy E., Eggermont A.M., Paci A., Robert C., Puppels G.J., and Mir L.M.** A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. [2017] *Cancer Research* (77) 2 : 557-565. Impact factor : 9.130
- Azouzi N., Caillox J., Cazarin J.M., Knauf J.A., Cracchiolo J., Al Ghuzlan A., Hartl D., Polak M., Carre A., El Mzibri M., Filali-Maltouf A., Al Bouzidi A., Schlumberger M., Fagin J.A., Ameziane-El-Hassani R., and Dupuy C.** NADPH Oxidase NOX4 Is a Critical Mediator of BRAFV600E-Induced Downregulation of the Sodium/Iodide Symporter in Papillary Thyroid Carcinomas. [2017] *Antioxidants and Redox Signaling* (26) 15 : 864-877. Impact factor : 6.530
- Baglietto L., Ponzi E., Haycock P., Hodge A., Bianca A.M., Jung C.H., Chung J., Fasanelli F., Guida F., Campanella G., Chadeau-Hyam M., Grankvist K., Johansson M., Ala U., Provero P., Ming W.E., Joo J., English D.R., Kazmi N., Lund E., Faltus C., Kaaks R., Risch A., Barrdahl M., Sandanger T.M., Southey M.C., Giles G.G., Johansson M., Vineis P., Polidoro S., Relton C.L., and Severi G.** DNA methylation changes measured in pre-diagnostic peripheral blood samples are associated with smoking and lung cancer risk. [2017] *International Journal of Cancer* (140) 1 : 50-61. Impact factor : 7.360
- Bahleda R., Grilley-Olson J.E., Govindan R., Barlesi F., Greillier L., Perol M., Ray-Coquard I., Strumberg D., Schultheis B., Dy G.K., Zalcman G., Weiss G.J., Walter A.O., Kornacker M., Rajagopalan P., Henderson D., Nogai H., Ocker M., and Soria J.C.** Phase I dose-escalation studies of roniciclib, a pancyclin-dependent kinase inhibitor, in advanced malignancies. [2017] *British Journal of Cancer* (116) 12 : 1505-1512. Impact factor : 5.922
- Bahougne T., Imperiale A., Averois G., Chabrier G., Burnichon N., Gimenez-Roqueplo A.P., Dali-Youcef N., Libe R., Baudin E., Roy C., Lang H., and Kessler L.** Successful response to pegylated interferon alpha in a recurrent paraganglioma. [2017] *Endocrine-Related Cancer* (24) 2 : L7-L11. Impact factor : 5.331
- Bailey H.D., Rios P., Lacour B., Guerrini-Rousseau L., Bertozzi A.I., Leblond P., Faure-Contier C., Pellier I., Freycon C., Michon J., Puget S., Ducassou S., Orsi L., and Clavel J.** Factors related to pregnancy and birth and the risk of childhood brain tumours: The ESTELLE and ESCALE studies (SFCE, France). [2017] *International Journal of Cancer* (140) 8 : 1757-1769. Impact factor : 7.360
- Bailleux C., Andre F., and Delaloge S.** Tumor-specific circulating angiogenic progenitors in breast and renal cell cancer: What prospects? [2017] *European Journal of Cancer* (77) : 153-154. Impact factor : 7.191
- Bamias A., Escudier B., Sternberg C.N., Zagouri F., Dellis A., Djavan B., Tzannis K., Kontovinis L., Stravodimos K., Papatsoris A., Mitropoulos D., Deliveliotis C., Dimopoulos M.A., and Constantinides C.A.** Current clinical practice guidelines for the treatment of renal cell carcinoma: A systematic review and critical evaluation. [2017] *Oncologist* (22) 6 : 667-679. Impact factor : 5.306
- Baraniskin A., Van Laethem J.L., Wyrwicz L., Guller U., Wasan H.S., Matysiak-Budnik T., Gruenberger T., Ducreux M., Carneiro F., Van Cutsem E., Seufferlein T., and Schmiegel W.** Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona. [2017] *European Journal of Cancer* (86) : 305-317. Impact factor : 7.191
- Bautista F., Moreno L., Marshall L., Pearson A.D.J., Geoerger B., and Paoletti X.** Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium. [2017] *European Journal of Cancer* (86) : 275-284. Impact factor : 7.191
- Belderbos J., Schagen S., Walraven I., Deprez S., de Ruiter M., De Ruyscher D., and Le Pechoux C.** In Regard to Redmond et al. [2017] *International Journal of Radiation Oncology Biology Physics* (99) 1 : 238-239. Impact factor : 5.554
- Benit P., Pelhaitre A., Saunier E., Bortoli S., Coulibaly A., Rak M., Schiff M., Kroemer G., Zeviani M., and Rustin P.** Paradoxical Inhibition of Glycolysis by Pioglitazone Opposes the Mitochondriopathy Caused by AIF Deficiency. [2017] *EBioMedicine* (17) : 75-87. Impact factor : 6.183
- Benusiglio P.R.** CDH1 germline mutations: different syndromes, same management? [2017] *Genetics in Medicine* (19) 9 : 965-966. Impact factor : 9.937
- Berdelou A., Boige V., Arfi-Rouche J., Malka D., Ederhy S., Izzedine H., Leboulleux S., Choungnet C.N., Burtin P., de Baere T., Laplanche A., Elias D., Schlumberger M., Scoazec J.Y., Ducreux M., and Baudin E.** Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study. [2017] *Neuroendocrinology* (105) 1 : 26-34. Impact factor : 5.024
- Bernard-Tessier A., Jeanville P., Champiat S., Lazarovici J., Voisin A.L., Mateus C., Lambotte O., Annereau M., and Michot J.M.** Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. [2017] *European Journal of Cancer* (81) : 135-137. Impact factor : 7.191
- Berry V., Basson L., Bogart E., Mir O., Blay J.Y., Italiano A., Bertucci F., Chevreau C., Clisat-Delaine S., Liegl-Antzager B., Tresch-Bruneel E., Wallet J., Taieb S., Decoupigny E., Le Cesne A., Brodowicz T., and Penel N.** REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis. [2017] *Cancer* (123) 12 : 2294-2302. Impact factor : 6.537
- Bertucci F., Finetti P., Perrot D., Leroux A., Collin F., Le Cesne A., Coindre J.M., Blay J.Y., Birnbaum D., and Mamessier E.** PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. [2017] *Oncology* (6) 3 : e1278100. Impact factor : 5.503
- Bigot F., Castanon E., Baldini C., Hollebecque A., Carmona A., Postel-Vinay S., Angevin E., Armand J.P., Ribrag V., Aspeslagh S., Varga A., Bahleda R., Menis J., Gazzah A., Michot J.M., Marabelle A., Soria J.C., and Massard C.** Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). [2017] *European Journal of Cancer* (84) : 212-218. Impact factor : 7.191
- Blanchard P. and Garden A.S.** In Regard to Arthurs et al. [2017] *International Journal of Radiation Oncology Biology Physics* (97) 2 : 440. Impact factor : 5.554
- Bloy N., Garcia P., Laumont C.M., Pitt J.M., Sistigu A., Stoll G., Yamazaki T., Bonneil E., Buque A., Humeau J., Drijfhout J.W., Meurice G., Walter S., Fritsche J., Weinschenk T., Rammensee H.G., Melief C., Thibault P., Perreault C., Pol J., Zitvogel L., Senovilla L., and Kroemer G.** Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. [2017] *Immunological reviews* (280) 1 : 165-174. Impact factor : 9.217
- Boia-Ferreira M., Basilio A.B., Hamasaki A.E., Matsubara F.H., Appel M.H., Da Costa C.R.V., Amson R., Telerman A., Chaim O.M., Veiga S.S., and Senff-Ribeiro A.** TCTP as a therapeutic target in melanoma treatment. [2017] *British Journal of Cancer* (117) 5 : 656-665. Impact factor : 5.922
- Boisseau W., Touat M., Berzero G., Savatovsky J., Marabelle A., Touitou V., Ricard D., Malouf G., and Psimaras D.** Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy. [2017] *European Journal of Cancer* (83) : 28-31. Impact factor : 7.191

- Boissenot T., Bordat A., Larrat B., Varna M., Chacun H., Paci A., Poinsignon V., Fattal E., and Tsapis N.** Ultrasound-induced mild hyperthermia improves the anticancer efficacy of both Taxol and paclitaxel-loaded nanocapsules. [2017] *Journal of Controlled Release* (264) : 219-227. Impact factor : 7.877
- Bonhomme B., Godbert Y., Perot G., Al Ghuzlan A., Bardet S., Belleanne G., Criniere L., Do Cao C., Fouilloux G., Guyetant S., Kelly A., Leboultoux S., Buffet C., Leteurtre E., Michels J.J., Tissier F., Toubert M.E., Wassef M., Pinard C., Hostein I., and Soubeyran I.** Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases. [2017] *Thyroid* (27) 5 : 682-692. Impact factor : 7.557
- Bou Saada Y., Zakharova V., Chernyak B., Dib C., Carnac G., Dokudovskaya S., and Vassetzky Y.S.** Control of DNA integrity in skeletal muscle under physiological and pathological conditions. [2017] *Cellular and Molecular Life Sciences* (79) 19 : 3439-3449. Impact factor : 6.721
- Brose M.S., Smit J., Lin C.C., Pitoia F., Fellous M., De Sanctis Y., Schlumberger M., Tori M., and Sugitani I.** Timing of multikinase inhibitor initiation in differentiated thyroid cancer. [2017] *Endocrine-Related Cancer* (24) 5 : 237-242. Impact factor : 5.331
- Bukreyeva I., Angoulvant A., Bendib I., Gagnard J.C., Bourhis J.H., Dargere S., Bonhomme J., Thellier M., Gachot B., and Wyplosz B.** Enterocytozoon bienesi microsporidiosis in stem cell transplant recipients treated with fumagillin. [2017] *Emerging Infectious Diseases* (23) 6 : 1039-1041. Impact factor : 7.422
- Cabel L., Loir E., Gravis G., Lavaud P., Massard C., Albiges L., Baciarello G., Loriot Y., and Fizazi K.** Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: Case report of two patients. [2017] *Journal for Immunotherapy of Cancer* (5) 1 : 31. Impact factor : 8.374
- Cabo M., Offringa R., Zitvogel L., Kroemer G., Muntasell A., and Galluzzi L.** Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. [2017] *Oncology* (6) 12 : e1371896. Impact factor : 5.503
- Cai T.T., Ye S.B., Liu Y.N., He J., Chen Q.Y., Mai H.Q., Zhang C.X., Cui J., Zhang X.S., Busson P., Zeng Y.X., and Li J.** LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma. [2017] *Plos Pathogens* (13) 7 : e1006503. Impact factor : 6.158
- Caini S., Masala G., Saieva C., Kvaskoff M., Savoye I., Sacerdote C., Hemmingsson O., Hammer Bech B., Overvad K., Tjonneland A., Petersen K.E., Mancini F.R., Boutron-Ruault M.C., Cervenka I., Kaaks R., Kuhn T., Boeing H., Floegel A., Trichopoulou A., Valanou E., Kritikon M., Tagliabue G., Panico S., Tumino R., Bueno-De-Mesquita H.B., Peeters P.H., Veierod M.B., Ghiasvand R., Lukic M., Quiros J.R., Chirlaque M.D., Ardanaz E., Salamanca Fernandez E., Larranaga N., Zamora-Ros R., Maria N.L., Ljuslander I., Jirstrom K., Sonestedt E., Key T.J., Wareham N., Khaw K.T., Gunter M., Huybrechts I., Murphy N., Tsilidis K.K., Weiderpass E., and Palli D.** Coffee, tea and melanoma risk: findings from the European Prospective Investigation into Cancer and Nutrition. [2017] *International Journal of Cancer* (140) 10 : 2246-2255. Impact factor : 7.360
- Calmon R., Puget S., Varlet P., Beccaria K., Blauwblomme T., Grevent D., Sainte-Rose C., Castel D., Dufour C., Dhermain F., Bolle S., Saitovitch A., Zilbovicius M., Brunelle F., Grill J., and Boddaert N.** Multimodal Magnetic Resonance Imaging of Treatment-Induced Changes to Diffuse Infiltrating Pontine Gliomas in Children and Correlation to Patient Progression-Free Survival. [2017] *International Journal of Radiation Oncology Biology Physics* (99) 2 : 476-485. Impact factor : 5.554
- Canaani J., Labopin M., Socie G., Nihtinen A., Huynh A., Cornelissen J., Deconinck E., Gedde-Dahl T., Forcade E., Chevallier P., Bourhis J.H., Blaise D., Mohty M., and Nagler A.** Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. [2017] *American Journal of Hematology* (92) 7 : 653-659. Impact factor : 5.303
- Carbannel F., Soularue E., Coutzac C., Chaput N., Mateus C., Lepage P., and Robert C.** Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? [2017] *Seminars in Immunopathology* (39) 3 : 327-331. Impact factor : 6.437
- Chargari C., Haie-Meder C., Guerin F., Minard-Colin V., de Lambert G., Mazon R., Escande A., Marsolat F., Dumas I., Deutsch E., Valteau-Couanet D., Audry G., Oberlin O., and Martelli H.** Brachytherapy Combined With Surgery for Conservative Treatment of Children With Bladder Neck and/or Prostate Rhabdomyosarcoma. [2017] *International Journal of Radiation Oncology Biology Physics* (98) 2 : 352-359. Impact factor : 5.554
- Chartier S., Mejean A., Richard S., Thiounn N., Vasiliu V., and Verkarre V.** Biphasic Squamous Alveolar Renal Cell Carcinoma: 2 Cases in a Family Supporting a Continuous Spectrum with Papillary Type i Renal Cell Carcinoma. [2017] *American Journal of Surgical Pathology* (41) 7 : 1011-1012. Impact factor : 5.878
- Chen L., Jenjaroenpun P., Pillai A.M., Ivshina A.V., Ow G.S., Efthimios M., Zhiqun T., Tan T.Z., Lee S.C., Rogers K., Ward J.M., Mori S., Adams D.J., Jenkins N.A., Copeland N.G., Ban K.H., Kuznetsov V.A., and Thierry J.P.** Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification. [2017] *Proceedings of the National Academy of Sciences of the United States of America* (114) 11 : E2215-E2224. Impact factor : 9.504
- Cheung W., Keski-Rahkonen P., Assi N., Ferrari P., Freisling H., Rinaldi S., Slimani N., Zamora-Ros R., Rundle M., Frost G., Gibbons H., Carr E., Brennan L., Cross A.J., Pala V., Panico S., Sacerdote C., Palli D., Tumino R., Kuhn T., Kaaks R., Boeing H., Floegel A., Mancini F., Boutron-Ruault M.C., Baglietto L., Trichopoulou A., Naska A., Orfanos P., and Scalbert A.** A metabolomic study of biomarkers of meat and fish intake. [2017] *American Journal of Clinical Nutrition* (105) 3 : 600-608. Impact factor : 6.549
- Chisholm J.C., Merks J.H.M., Casanova M., Bisogno G., Orbach D., Gentet J.C., Thomassin-Defachelles A.S., Chastagner P., Louis S., Ronghe M., McHugh K., van Rijn R.R., Hilton M., Bachir J., Furst-Recktenwald S., Georger B., Oberlin O., and European paediatric Soft tissue sarcoma Study Group (EpSSG) and the European Innovative Therapies for Children with Cancer (ITCC) Consortium.** Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). [2017] *European Journal of Cancer* (83) : 177-184. Impact factor : 7.191
- Chouaib S., Noman M.Z., Kosmatopoulos K., and Curran M.A.** Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. [2017] *Oncogene* (36) 4 : 439-445. Impact factor : 6.854
- Clemenson C., Chargari C., Liu W., Mondini M., Ferte C., Burbridge M.F., Cattani V., Jaquet-Bescond A., and Deutsch E.** The MET/AXL/FGFR inhibitor S49076 impairs Aurora B activity and improves the antitumor efficacy of radiotherapy. [2017] *Molecular Cancer Therapeutics* (16) 10 : 2107-2119. Impact factor : 5.365
- Cohen K.J., Jabado N., and Grill J.** Diffuse intrinsic pontine gliomas - Current management and new biological insights. Is there a glimmer of hope? [2017] *Neuro-Oncology* (19) 8 : 1025-1034. Impact factor : 9.384
- Cohen R., Buhard O., Cervera P., Hain E., Dumont S., Bardier A., Bachet J.B., Gornet J.M., Lopez-Trabada D., Dumont S., Kaci R., Bertheau P., Renaud F., Bibeau F., Parc Y., Vernerey D., Duval A., Svrcek M., and Andre T.** Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. [2017] *European Journal of Cancer* (86) : 266-274. Impact factor : 7.191

- Colomba E., Le Teuff G., Eisen T., Stewart G.D., Fife K., Larkin J., Biondo A., Pickering L., Srinivasan A., Boyle H., Derosa L., Sternberg C.N., Recine F., Ralph C., Saldana C., Barthelemy P., Bernhard J.C., Gurney H., Verhoest G., Vauleon E., Bigot P., Berger J., Pfister C., Gravis G., Rodier J.M., Culine S., Caty A., Rolland F., Priou F., Escudier B., and Albiges L.** Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. [2017] *European Journal of Cancer* (80) : 55-62. Impact factor : 7.191
- Cornelis G., Funk M., Vernochet C., Leal F., Tarazona O.A., Meurice G., Heidmann O., Dupressoir A., Miralles A., Ramirez-Pinilla M.P., and Heidmann T.** An endogenous retroviral envelope syncytin and its cognate receptor identified in the viviparous placental Mabuya lizard. [2017] *Proceedings of the National Academy of Sciences of the United States of America* (114) 51 : E10991-E11000. Impact factor : 9.504
- Coutzac C., Adam J., Soularue E., Collins M., Racine A., Mussini C., Boselli L., Kamsukom N., Mateus C., Charrier M., Cassard L., Plancharat D., Ribrag V., Fizazi K., Loriot Y., Lepage P., Scoazec J.Y., Robert C., Carbonnel F., and Chaput N.** Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. [2017] *Journal of Crohn's & colitis* (11) 10 : 1238-1246. Impact factor : 6.637
- Craveiro M., Cretenet G., Mongellaz C., Matias M.I., Caron O., de Lima M.C.P., Zimmermann V.S., Solary E., Dardalhon V., Dulic V., and Taylor N.** Resveratrol stimulates the metabolic reprogramming of human CD4(+) T cells to enhance effector function. [2017] *Science signaling* (10) 501 : eaal3024. Impact factor : 6.378
- Curtit E., Pivot X., Henriques J., Paget-Bailly S., Fumoleau P., Rios M., Bonnefoi H., Bachelot T., Soulie P., Jouannaud C., Bourgeois H., Petit T., Tennevet I., Assouline D., Mathieu M.C., Jacquin J.P., Lavau-Denes S., Darut-Jouve A., Ferrero J.M., Tarpin C., Levy C., Delecroix V., Trillet-Lenoir V., Cojocarasu O., Meunier J., Pierga J.Y., Kerbrat P., Faure-Mercier C., Blanche H., Sahbatou M., Boland A., Bacq D., Besse C., Thomas G., Deleuze J.F., Pauporte I., Romieu G., and Cox D.G.** Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinicopathological characteristics and outcomes. [2017] *Breast Cancer Research* (19) 1 : 98. Impact factor : 6.142
- Dantas-Barbosa C., Lesluyes T., Loarer F.L., Chibon F., Treilleux I., Coindre J.M., Meeus P., Brahmi M., Bally O., Ray-Coquard I., Sunyach M.P., Le Cesne A., Mir O., Bonvalot S., Toulmonde M., Italiano A., Saintigny P., Jean-Denis M., Ducimetiere F., Ranchere D., El S.H., Alberti L., and Blay J.Y.** Expression and role of TYRO3 and AXL as potential therapeutic targets in leiomyosarcoma. [2017] *British Journal of Cancer* (117) 12 : 1787-1797. Impact factor : 5.922
- Daroles J., Borget I., Suci V., Mazouni C., Delaloge S., and Balleyguier C.** Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful? [2017] *European Journal of Cancer* (85) : 23-30. Impact factor : 7.191
- de Baere T., Tselikas L., Yevich S., Boige V., Deschamps F., Ducreux M., Goere D., Nguyen F., and Malka D.** The role of image-guided therapy in the management of colorectal cancer metastatic disease. [2017] *European Journal of Cancer* (75) : 231-242. Impact factor : 7.191
- de Jonge M., de Weger V.A., Dickson M.A., Langenberg M., Le Cesne A., Wagner A.J., Hsu K., Zheng W., Mace S., Tuffal G., Thomas K., and Schellens J.H.** A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours. [2017] *European Journal of Cancer* (76) : 144-151. Impact factor : 7.191
- De Velasco G., Culhane A.C., Fay A.P., Ari Hakimi A., Voss M.H., Tannir N.M., Tamboli P., Appleman L.J., Bellmunt J., Kimryn Rathmell W., Albiges L., Hsieh J.J., Heng D.Y.C., Signoretti S., and Choueiri T.K.** Molecular subtypes improve prognostic value of international metastatic renal cell carcinoma database consortium prognostic model. [2017] *Oncologist* (22) 3 : 286-292. Impact factor : 5.306
- Deandreis D.** Reply: Fixed 3.7-GBq 131I Activity for Metastatic Thyroid Cancer Therapy Ignores Science and History. [2017] *Journal of Nuclear Medicine* (58) 9 : 1531. Impact factor : 7.439
- Deandreis D., Rubino C., Tala H., Leboulleux S., Terroir M., Baudin E., Larson S., Fagin J.A., Schlumberger M., and Tuttle R.M.** Comparison of Empiric Versus Whole-Body/Blood Clearance Dosimetry Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. [2017] *Journal of Nuclear Medicine* (58) 5 : 717-722. Impact factor : 7.439
- Deandreis D., Schlumberger M., and Tuttle R.M.** Reply : Comparison of Empiric Versus Dosimetry-Guided Radioiodine Therapy: The Devil Is in the Details. [2017] *Journal of Nuclear Medicine* (58) 5 : 863-864. Impact factor : 7.439
- Del Re M., Fogli S., Derosa L., Massari F., De Souza P., Crucitta S., Bracarda S., Santini D., and Danesi R.** The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. [2017] *Cancer Treatment Reviews* (55) : 71-82. Impact factor : 8.122
- Delaunay J., Martin L., Bressac de Paillerets B., Duru G., Ingster O., and Thomas L.** Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3. [2017] *JAMA dermatology* (153) 11 : 1122-1129. Impact factor : 8.107
- Delestre L., Cui H., Esposito M., Quiveron C., Mylonas E., Penard-Lacronique V., Bischof O., and Guillouf C.** Senescence is a Spi1-induced anti-proliferative mechanism in primary hematopoietic cells. [2017] *Haematologica* (102) 11 : 1850-1860. Impact factor : 9.090
- Di Meglio A., Lin N.U., Freedman R.A., Barry W.T., Winer E.P., and Vaz-Luis I.** Patterns of utilization of imaging studies and serum tumor markers among patients with de novo metastatic breast cancer. [2017] *JNCCN Journal of the National Comprehensive Cancer Network* (15) 3 : 316-324. Impact factor : 6.471
- Dobay M.P., Lemonnier F., Missiaglia E., Bastard C., Vallois D., Jais J.P., Scourzic L., Dupuy A., Fataccioli V., Pujals A., Parrens M., Le Bras F., Rousset T., Picquenot J.M., Martin N., Haioun C., Delarue R., Bernard O.A., DeLorenzi M., de Leval L., and Gaulard P.** Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. [2017] *Haematologica* (102) 4 : e148-e151. Impact factor : 9.090
- Duchmann M., Braun T., Micol J.B., Platzbecker U., Park S., Pilorge S., Beyne-Rauzy O., Vey N., Sebert M., Gruson B., Dumas P.Y., Guieze R., Chretien M.L., Laribi K., Chait Y., Legros L., Sahnes L., Hirsch P., Salanoubat C., Solary E., Fenaux P., and Itzykson R.** Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents. [2017] *Blood cancer journal* (7) 5 : e562. Impact factor : 8.125
- Duell E.J., Lujan-Barroso L., Sala N., Deitz M.S., Overvad K., Tjonneland A., Olsen A., Weiderpass E., Busund L.T., Moi L., Muller D., Vineis P., Aune D., Matullo G., Naccarati A., Panico S., Tagliabue G., Tumino R., Palli D., Kaaks R., Katzke V.A., Boeing H., Bueno-de-Mesquita H.B.A., Peeters P.H., Trichopoulou A., Lagiou P., Kotanidou A., Travis R.C., Wareham N., Khaw K.T., Ramon Q.J., Rodriguez-Barranco M., Dorransoro M., Chirilaque M.D., Ardanaz E., Severi G., Boutron-Ruault M.C., Rebours V., Brennan P., Gunter M., Scelo G., Cote G., Sherman S., and Kork M.** Plasma microRNAs as biomarkers of pancreatic cancer risk in a prospective cohort study. [2017] *International Journal of Cancer* (141) 5 : 905-915. Impact factor : 7.360

- Dufies M., Giuliano S., Viotti J., Borchiellini D., Cooley L.S., Ambrosetti D., Guyot M., Ndiaye P.D., Parola J., Claren A., Schiappa R., Gal J., Frangeul A., Jacquet A., Cassuto O., Grepin R., Auberger P., Bikfalvi A., Milano G., Escudier B., Rioux-Leclercq N., Porta C., Negrier S., Chamorey E., Ferrero J.M., and Pages G.** CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas. [2017] *British Journal of Cancer* (117) 7 : 947-953. Impact factor : 5.922
- Dupain C., Harttrampf A.C., Urbinati G., Geogerger B., and Massaad-Massade L.** Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine. [2017] *Molecular Therapy - Nucleic Acids* (6) : 315-326. Impact factor : 5.660
- Eggermont A.M.M. and Dummer R.** The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients. [2017] *European Journal of Cancer* (86) : 101-105. Impact factor : 7.191
- Eggink F.A., Van Gool I.C., Leary A., Pollock P.M., Crosbie E.J., Mileshkin L., Jordanova E.S., Adam J., Freeman-Mills L., Church D.N., Creutzberg C.L., de Bruyn M., Nijman H.W., and Bosse T.** Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. [2017] *Oncology* (6) 2 : e1264565. Impact factor : 5.503
- El-Fayech C., Haddy N., Allodji R.S., Veres C., Diop F., Kahlouche A., Llanas D., Jackson A., Rubino C., Guibout C., Pacquement H., Oberlin O., Thomas-Teinturier C., Scarabin P.Y., Chavaudra J., Lefkopoulos D., Giroud M., Bejot Y., Bernier V., Carrie C., Diallo I., and De Vathaire F.** Cerebrovascular Diseases in Childhood Cancer Survivors: Role of the Radiation Dose to Willis Circle Arteries. [2017] *International Journal of Radiation Oncology Biology Physics* (97) 2 : 278-286. Impact factor : 5.554
- El-Sayed I.Y., Daher A., Destouches D., Firtlej V., Kostallari E., Maille P., Huet E., Haidar-Ahmad N., Jenster G., de la Taille A., Abou M.R., Terry S., and Vacherot F.** Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling. [2017] *Cancer letters* (410) : 100-111. Impact factor : 6.491
- Emens L.A., Ascierto P.A., Darcy P.K., Demaria S., Eggermont A.M.M., Redmond W.L., Seliger B., and Marincola F.M.** Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. [2017] *European Journal of Cancer* (81) : 116-129. Impact factor : 7.191
- Escande A., Van Gestel D., Lacornerie T., Marchesi V., Florescu C., Guemnie-Tafo A., Peiffert D., Lisbona A., Deutsch E., and Mirabel X.** In Regard to Perrier et al. [2017] *International Journal of Radiation Oncology Biology Physics* (97) 1 : 204-205. Impact factor : 5.554
- Escande A., Haie-Meder C., Mazon R., Maroun P., Cavalcanti A., de Crevoisier R., Schernberg A., Marsolat F., Blanchard P., Martinetti F., Bossi A., Dumas I., Deutsch E., and Chargari C.** Brachytherapy for Conservative Treatment of Invasive Penile Carcinoma: Prognostic Factors and Long-Term Analysis of Outcome. [2017] *International Journal of Radiation Oncology Biology Physics* (99) 3 : 563-570. Impact factor : 5.554
- Facchinetti F., Rossi G., Bria E., Soria J.C., Besse B., Minari R., Friboulet L., and Tiseo M.** Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition. [2017] *Cancer Treatment Reviews* (55) : 83-95. Impact factor : 8.122
- Fedirko V., Tran H.O., Gewirtz A.T., Stepien M., Trichopoulou A., Aleksandrova K., Olsen A., Tjonneland A., Overvad K., Carbonnel F., Boutron-Ruault M.C., Severi G., Kuhn T., Kaaks R., Boeing H., Bamia C., Lagiou P., Grioni S., Panico S., Palli D., Tumino R., Naccarati A., Peeters P.H., Bueno-De-Mesquita H.B., Weiderpass E., Castano J.M., Barricarte A., Sanchez M.J., Dorronsoro M., Quiros J.R., Agudo A., Sjoberg K., Ohlsson B., Hemmingsson O., Werner M., Bradbury K.E., Khaw K.T., Wareham N., Tsilidis K.K., Aune D., Scalbert A., Romieu I., Riboli E., and Jenab M.** Exposure to bacterial products lipopolysaccharide and flagellin and hepatocellular carcinoma: a nested case-control study. [2017] *Bmc Medicine* (15) 1 : 72. Impact factor : 9.088
- Fend L., Rusakiewicz S., Adam J., Bastien B., Caignard A., Messaoudene M., Iribarren C., Cremer I., Marabelle A., Borg C., Semeraro M., Barraud L., Limacher J.M., Eggermont A., Kroemer G., and Zitvogel L.** Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. [2017] *Oncology* (6) 1 : e1163456. Impact factor : 5.503
- Fend L., Yamazaki T., Remy C., Fahrner C., Gantzer M., Nourtier V., Preville X., Quemener E., Kepp O., Adam J., Marabelle A., Pitt J.M., Kroemer G., and Zitvogel L.** Immune checkpoint blockade, immunogenic chemotherapy or IFN- α blockade boost the local and abscopal effects of oncolytic virotherapy. [2017] *Cancer Research* (77) 15 : 4146-4157. Impact factor : 9.130
- Ferme C., Thomas J., Brice P., Casasnovas O., Vranovsky A., Bologna S., Lugtenburg P.J., Bouabdallah R., Carde P., Sebban C., Eghbali H., Salles G., van Imhoff G.W., Thyss A., Noordijk E.M., Reman O., Lybeert M.L.M., Janvier M., Spina M., Audhuy B., Raemaekers J.M.M., Delarue R., Anglaret B., de Weerd O., Marjanovic Z., Tersteeg R.J.H.A., de Jong D., Briere J., Henry-Amar M., and Groupe d'Étude des Lymphomes de l'Adulte ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial. [2017] *European Journal of Cancer* (81) : 45-55. Impact factor : 7.191**
- Fernandez A.F., Barcena C., Martinez-Garcia G.G., Tamargo-Gomez I., Suarez M.F., Pietrocola F., Castoldi F., Esteban L., Sierra-Filardi E., Boya P., Lopez-Otin C., Kroemer G., and Marino G.** Autophagy counteracts weight gain, lipotoxicity and pancreatic beta-cell death upon hypercaloric pro-diabetic regimens. [2017] *Cell Death & Disease* (8) 8 : e2970. Impact factor : 5.638
- Ferrara R., Mezquita L., Auclin E., Chaput N., and Besse B.** Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter? [2017] *Cancer Treatment Reviews* (60) : 60-68. Impact factor : 8.122
- Ferrari E., Monzani R., Vilella V.R., Esposito S., Saluzzo F., Rossin F., D'Eletto M., Tosco A., De Gregorio F., Izzo V., Maiuri M.C., Kroemer G., Raia V., and Maiuri L.** Cysteamine re-establishes the clearance of *Pseudomonas aeruginosa* by macrophages bearing the cystic fibrosis-relevant F508del-CFTR mutation. [2017] *Cell Death & Disease* (8) 1 : e2544. Impact factor : 5.638
- Ferte C. and Marabelle A.** iRECIST: A clarification of tumour response assessment in the immunotherapy era. [2017] *European Journal of Cancer* (77) : 165-167. Impact factor : 7.191
- Fezai M., Slaymi C., Ben-Attia M., Kroemer G., Lang F., and Jemaa M.** Inhibition of colon carcinoma cell migration following treatment with purified venom from lesser weever fish (*Trachinus vipera*). [2017] *Cellular Physiology and Biochemistry* (41) 6 : 2279-2288. Impact factor : 5.500
- Forissier V., Tallet A., Cohen M., Classe J.M., Reyat F., Chopin N., Mazouni C., Gimbergues P., Darai E., Colombo P.E., Azuar P., Lambaudie E., and Houvenaeghel G.** Is post-mastectomy radiation therapy contributive in pN0-1mi breast cancer patients? Results of a French multi-centric cohort. [2017] *European Journal of Cancer* (87) : 47-57. Impact factor : 7.191
- Fortner R.T., Sarink D., Schock H., Johnson T., Tjonneland A., Olsen A., Overvad K., Affret A., His M., Boutron-Ruault M.C., Boeing H., Trichopoulou A., Naska A., Orfanos P., Palli D., Sieri S., Mattiello A., Tumino R., Ricceri F., Bueno-De-Mesquita H.B., Peeters P.H., Van Gils C.H., Weiderpass**

- E., Lund E., Quiros J.R., Agudo A., Sanchez M.J., Chirlaque M.D., Ardanaz E., Dorronsoro M., Key T., Khaw K.T., Rinaldi S., Dossus L., Gunter M., Merritt M.A., Riboli E., and Kaaks R.** Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort. [2017] *Bmc Medicine* (15) 1 : 26. Impact factor : 9.088
- Fortner R.T., Husing A., Kuhn T., Konar M., Overvad K., Tjonneland A., Hansen L., Boutron-Ruault M.C., Severi G., Fournier A., Boeing H., Trichopoulos A., Benetou V., Orfanos P., Masala G., Agnoli C., Mattiello A., Tumino R., Sacerdote C., Bueno-De-Mesquita H.B., Peeters P.H., Weiderpass E., Gram I.T., Gavrilyuk O., Quiros J.R., Huerta J.M., Ardanaz E., Larranaga N., Lujan-Barroso L., Sanchez-Cantalejo E., Butt S.T., Borgquist S., Idahl A., Lundin E., Khaw K.T., Allen N.E., Rinaldi S., Dossus L., Gunter M., Merritt M.A., Tzoulaki I., Riboli E., and Kaaks R.** Endometrial cancer risk prediction including serum-based biomarkers: Results from the EPIC cohort. [2017] *International Journal of Cancer* (140) 6 : 1317-1323. Impact factor : 7.360
- Foulfouin M., Graillet E., Adham M., Rousset P., Forestier J., Hervieu V., Robinson P., Scoazec J.Y., Lombard-Bohas C., and Walter T.** Treatment of metastatic pancreatic neuroendocrine tumors: relevance of ENETS 2016 guidelines. [2017] *Endocrine-Related Cancer* (24) 2 : 71-78. Impact factor : 5.331
- Fouquet B., Pawlikowska P., Caburet S., Guigon C., Makinen M., Tanner L., Hietala M., Urbanska K., Bellutti L., Legois B., Bessieres B., Gougeon A., Benachi A., Livera G., Rosselli F., Veitia R.A., and Misrahi M.** A homozygous FANCM mutation underlies a familial case of non-syndromic primary ovarian insufficiency. [2017] *eLife* (6) : e30490. Impact factor : 7.616
- Fournier C., Martin F., Zitvogel L., Kroemer G., Galluzzi L., and Apetoh L.** Trial Watch: Adoptively transferred cells for anticancer immunotherapy. [2017] *Oncolmmunology* (6) 11 : e1363139. Impact factor : 5.503
- Frazao A., Colombo M., Fourmentraux-Neves E., Messaoudene M., Rusakiewicz S., Zitvogel L., Vivier E., Vely F., Faure F., Dreno B., Benlalam H., Bouquet F., Savina A., Pasmant E., Toubert A., Avril M.F., and Caignard A.** Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib. [2017] *Cancer Immunology Research* (5) 7 : 582-593. Impact factor : 9.188
- Galldiks N., Albert N.L., Sommerauer M., Grosu A.L., Ganswindt U., Law I., Preusser M., Le Rhun E., Vogelbaum M.A., Zadeh G., Dhermain F., Weller M., Langen K.J., and Tonn J.C.** PET Imaging in Patients with Meningioma - Report of the RANO/PET Group. [2017] *Neuro-Oncology* (19) 12 : 1576-1587. Impact factor : 9.384
- Galluzzi L., Bravo-San Pedro J.M., and Kroemer G.** Mitophagy: Permitted by Prohibitin. [2017] *Current Biology* (27) 2 : R73-R76. Impact factor : 9.251
- Galluzzi L. and Kroemer G.** Novel immune checkpoint blocker to treat Merkel cell carcinoma. [2017] *Oncolmmunology* (6) 6 : e1315496. Impact factor : 5.503
- Galluzzi L. and Kroemer G.** Calreticulin and type I interferon: An unsuspected connection. [2017] *Oncolmmunology* (6) 3 : e1288334. Impact factor : 5.503
- Galluzzi L. and Kroemer G.** An epigenetic modifier triggers therapeutic immune responses against breast cancer. [2017] *Oncolmmunology* (6) 5 : e1313376. Impact factor : 5.503
- Garg A.D., More S., Rufo N., Mece O., Sassano M.L., Agostinis P., Zitvogel L., Kroemer G., and Galluzzi L.** Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. [2017] *Oncolmmunology* (6) 12 : e1386829. Impact factor : 5.503
- Garg A.D., Vara P.M., Schaaf M., Agostinis P., Zitvogel L., Kroemer G., and Galluzzi L.** Trial watch: Dendritic cell-based anticancer immunotherapy. [2017] *Oncolmmunology* (6) 7 : e1328341. Impact factor : 5.503
- Gauthier L., Corgnac S., Boutet M., Gros G., Validire P., Bismuth G., and Mami-Chouaib F.** Paxillin binding to the cytoplasmic domain of CD103 promotes cell adhesion and effector functions for CD8+ resident memory T cells in tumors. [2017] *Cancer Research* (77) 24 : 7072-7082. Impact factor : 9.130
- Geoerger B., Bergeron C., Gore L., Sender L., Dunkel I.J., Herzog C., Brochez L., Cruz O., Nysom K., Berghorn E., Simsek B., Shen J., and Pappo A.** Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. [2017] *European Journal of Cancer* (86) : 358-363. Impact factor : 7.191
- Ghamlouch H., Nguyen-Khac F., and Bernard O.A.** Chronic lymphocytic leukaemia genomics and the precision medicine era. [2017] *British Journal of Haematology* (178) 6 : 852-870. Impact factor : 5.128
- Gheghiani L., Loew D., Lombard B., Mansfeld J., and Gavet O.** PLK1 Activation in Late G2 Sets Up Commitment to Mitosis. [2017] *Cell Reports* (19) 10 : 2060-2073. Impact factor : 8.032
- Ghinagow R., De Meester J., Cruz L.J., Aspod C., Corgnac S., Macho-Fernandez E., Soulard D., Fontaine J., Chaperot L., Charles J., Soncin F., Mami-Chouaib F., Plumas J., Faveeuw C., and Trottein F.** Co-delivery of the NKT agonist alpha-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses. [2017] *Oncolmmunology* (6) 9 : e1339855. Impact factor : 5.503
- Giacchetti S., Hamy A.S., Delaloge S., Brain E., Berger F., Sigal-Zafrani B., Mathieu M.C., Bertheau P., Guinebreteiere J.M., Saghathchian M., Lerebours F., Mazouni C., Tembo O., Espie M., Reyat F., Marty M., Asselain B., and Pierga J.Y.** Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status. [2017] *European Journal of Cancer* (75) : 323-332. Impact factor : 7.191
- Gizzi M., Oberic L., Massard C., Poterie A., Le Teuff G., Lorient Y., Albiges L., Baciarello G., Michels J., Bossi A., Blanchard P., Escudier B., and Fizazi K.** Corrigendum to «Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours» [Eur J Cancer 69 (2016) 151-157]. [2017] *European Journal of Cancer* (75) : 333. Impact factor : 7.191
- Glorian V., Allegre J., Berthelet J., Dumetier B., Boutanquoi P.M., Droin N., Kayaci C., Cartier J., Gemble S., Marcion G., Gonzalez D., Boidot R., Garrido C., Michaud O., Solary E., and Dubrez L.** DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues. [2017] *Cell Death & Disease* (8) 5 : e2816. Impact factor : 5.638
- Gnekow A.K., Walker D.A., Kandels D., Picton S., Perilongo G., Grill J., Stokland T., Sandstrom P.E., Warmuth-Metz M., Pietsch T., Giangaspero F., Schmidt R., Faldum A., Kilmartin D., De Paoli A., and De Salvo G.L.** A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (<= 16 years) low grade glioma - A final report. [2017] *European Journal of Cancer* (81) : 206-225. Impact factor : 7.191
- Gomez-Brouchet A., Illac C., Gilhodes J., Bouvier C., Aubert S., Guinebreteiere J.M., Marie B., Larousserie F., Entz-Werte N., de Pinieux G., Filleron T., Minard V., Minville V., Mascard E., Gouin F., Jimenez M., Le Deley M.C., Piperno-Neumann S., Brugieres L., and Redini F.** CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies from the French OS2006 phase 3 trial. [2017] *Oncolmmunology* (6) 9 : e1331193. Impact factor : 5.503
- Granier C., Dariane C., Combe P., Verkarre V., Urien S., Badoual C., Roussel H.,**

- Mandavit M., Ravel P., Sibony M., Biard L., Radulescu C., Vinatier E., Benhamouda N., Peyroumaire M., Oudard S., Mejean A., Timsit M.O., Gey A., and Tartour E.** Tim-3 expression on tumor-infiltrating PD-1+CD8+T cells correlates with poor clinical outcome in renal cell carcinoma. [2017] *Cancer Research* (77) 5 : 1075-1082. Impact factor : 9.130
- Gravis G., Audenet F., Irani J., Timsit M.O., Barthelemy P., Beuzeboc P., Flechon A., Linassier C., Oudard S., Rebillard X., Richaud P., Roupret M., Thiery V.A., Vincendeau S., Albiges L., and Rozet F.** Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature. [2017] *Cancer Treatment Reviews* (55) : 211-217. Impact factor : 8.122
- Hamid O., Puzanov I., Dummer R., Schachter J., Daud A., Schadendorf D., Blank C., Cranmer L.D., Robert C., Pavlick A.C., Gonzalez R., Hodi F.S., Ascierto P.A., Salama A.K.S., Margolin K.A., Gangadhar T.C., Wei Z., Ebbinghaus S., Ibrahim N., and Ribas A.** Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. [2017] *European Journal of Cancer* (86) : 37-45. Impact factor : 7.191
- Haque F., Varlet P., Puntonet J., Storer L., Bountali A., Rahman R., Grill J., Carcaboso A.M., Jones C., Layfield R., and Grundy R.G.** Evaluation of a novel antibody to define histone 3 G34R mutant brain tumours. [2017] *Acta neuropathologica communications* (5) 1 : 45. Impact factor : 5.414
- Hasmim M., Khalife N., Zhang Y., Doldur M., Visentin G., Terry S., Giron-Michel J., Tang R., Delhommeau F., Dulphy N., Bourhis J.H., Louache F., and Chouaib S.** Expression of CD94 by ex vivo-differentiated NK cells correlates with the in vitro and in vivo acquisition of cytotoxic features. [2017] *Oncolimmunology* (6) 10 : e1346763. Impact factor : 5.503
- Haugen B.R., Sawka A.M., Alexander E.K., Bible K.C., Caturegli P., Doherty G.M., Mandel S.J., Morris J.C., Nassar A., Pacini F., Schlumberger M., Schuff K., Sherman S.I., Somers H., Sosa J.A., Steward D.L., Wartofsky L., and Williams M.D.** American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. [2017] *Thyroid* (27) 4 : 481-483. Impact factor : 7.557
- Heidmann O., Beguin A., Paternina J., Berthier R., Deloger M., Bawa O., and Heidmann T.** HEMO, an ancestral endogenous retroviral envelope protein shed in the blood of pregnant women and expressed in pluripotent stem cells and tumors. [2017] *Proceedings of the National Academy of Sciences of the United States of America* (114) 32 : E6642-E6651. Impact factor : 9.504
- Heudel P.E., Fabbro M., Roemer-Becuwe C., Kaminsky M.C., Arnaud A., Joly F., Roche-Forestier S., Meunier J., Foa C., You B., Priou F., Tazi Y., Floquet A., Selle F., Berton-Rigaud D., Lesoin A., Kalbacher E., Lortholary A., Favier L., Treilleux I., and Ray-Coquard I.** Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: A stratified type I-type II study from the GINECO group. [2017] *British Journal of Cancer* (116) 3 : 303-309. Impact factor : 5.922
- Hollebecque A., Bahleda R., Faivre L., Adam J., Poincignon V., Paci A., Gomez-Roca C., Thery J.C., Le Deley M.C., Varga A., Gazzah A., Ileana E., Gharib M., Angevin E., Malekzadeh K., Massard C., Soria J.C., and Spano J.P.** Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. [2017] *European Journal of Cancer* (81) : 81-89. Impact factor : 7.191
- Huang J., Zagai U., Hallmans G., Nyren O., Engstrand L., Stolzenberg-Solomon R., Duell E.J., Overvad K., Katzke V.A., Kaaks R., Jenab M., Park J.Y., Murillo R., Trichopoulou A., Lagiou P., Bamia C., Bradbury K.E., Riboli E., Aune D., Tsilidis K.K., Capella G., Agudo A., Krogh V., Palli D., Panico S., Weiderpass E., Tjonneland A., Olsen A., Martinez B., Redondo-Sanchez D., Chirlaque M.D., Peeters P.H., Regner S., Lindkvist B., Naccarati A., Ardanaz E., Larranaga N., Boutron-Ruault M.C., Rebours V., Barre A., Bueno-De-Mesquita H.B., and Ye W.** Helicobacter pylori infection, chronic corpus atrophic gastritis and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort: a nested case-control study. [2017] *International Journal of Cancer* (140) 8 : 1727-1735. Impact factor : 7.360
- Huet S., Xerri L., Tesson B., Mareschal S., Taix S., Mescam-Mancini L., Sohier E., Carrere M., Lazarovici J., Casasnovas O., Tonon L., Boyault S., Hayette S., Haioun C., Fabiani B., Viari A., Jardin F., and Salles G.** EZH2 alterations in follicular lymphoma: biological and clinical correlations. [2017] *Blood cancer journal* (7) 4 : e555. Impact factor : 8.125
- Ibrahim T., Routier E., Weill A., Baz M., and Robert C.** Successful re-challenge with anti-BRAF and anti-MEK in a patient with symptomatic melanoma flare. [2017] *European Journal of Cancer* (82) : 25-26. Impact factor : 7.191
- Ives N.J., Suci S., Eggermont A.M.M., Kirkwood J., Lorigan P., Markovic S.N., Garbe C., and Wheatley K.** Adjuvant interferon-alpha for the treatment of high-risk melanoma: An individual patient data meta-analysis. [2017] *European Journal of Cancer* (82) : 171-183. Impact factor : 7.191
- Jacquelot N., Pitt J.M., Enot D.P., Roberti M.P., Duong C.P.M., Rusakiewicz S., Eggermont A.M., and Zitvogel L.** Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. [2017] *Oncolimmunology* (6) 8 : e1299303. Impact factor : 5.503
- Janke C. and Montagnac G.** Causes and Consequences of Microtubule Acetylation. [2017] *Current Biology* (27) 23 : R1287-R1292. Impact factor : 9.251
- Janssens G.O., Gandola L., Bolle S., Mandeville H., Ramos-Albiac M., van Beek K., Benghiat H., Hoeben B., Morales La Madrid A., Kortmann R.D., Hargrave D., Menten J., Pecori E., Biassoni V., von Bueren A.O., van Vuurden D.G., Massimino M., Sturm D., Peters M., and Kramm C.M.** Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. [2017] *European Journal of Cancer* (73) : 38-47. Impact factor : 7.191
- Joensuu H., Blay J.Y., Comandone A., Martin-Broto J., Fumagalli E., Grignani G., Del Muro X.G., Adenis A., Valverde C., Pousa A.L., Bouche O., Italiano A., Bauer S., Barone C., Weiss C., Crippa S., Camozzi M., Castellana R., and Le Cesne A.** Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. [2017] *British Journal of Cancer* (117) 9 : 1278-1285. Impact factor : 5.922
- Jouenne F., de Beauchene I.C., Bollaert E., Avril M.F., Caron O., Ingster O., Le Cesne A., Benusiglio P., Terrier P., Caumette V., Pissaloux D., De La Fouchardiere A., Cabaret O., N'Diaye B., Velghe A., Bougeard G., Mann G.J., Koscielny S., Barrett J.H., Harland M., Newton-Bishop J., Gruis N., Van Doorn R., Gauthier-Villars M., Pierron G., Stoppa-Lyonnet D., Coupier I., Guimbaud R., Delnatte C., Scoazec J.Y., Eggermont A.M., Feunteun J., Tchertanov L., Demoulin J.B., Frebourg T., and Bressac de Paillerets B.** Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma. [2017] *Journal of Medical Genetics* (54) 9 : 607-612. Impact factor : 5.751
- Jouinot A., Assie G., Libe R., Fassnacht M., Papiathomas T., Barreau O., De La Villeon B., Faillot S., Hamzaoui N., Neou M., Perlemoine K., Rene-Corail F., Rodriguez S., Sibony M., Tissier F., Dousset B., Sbiara S., Ronchi C., Kroiss M., Korpershoek E., De Krijger R., Waldmann J., Bartsch D.K., Quinkler M., Haissaguerre M., Tabarin A., Chabre O., Sturm N., Luconi M., Mantero F.,**

- Mannelli M., Cohen R., Kerlan V., Touraine P., Barrande G., Groussin L., Bertagna X., Baudin E., Amar L., Beuschlein F., Clauser E., Coste J., and Bertherat J.** DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. [2017] *Journal of Clinical Endocrinology & Metabolism* (102) 3 : 923-932. Impact factor : 5.789
- Joyon N., Tauziede-Espariat A., Alentorn A., Giry M., Castel D., Capelle L., Zanello M., Varlet P., and Bielle F.** K27M mutation in H3F3A in ganglioglioma grade I with spontaneous malignant transformation extends the histopathological spectrum of the histone H3 oncogenic pathway. [2017] *Neuropathology and Applied Neurobiology* (43) 3 : 271-276. Impact factor : 6.059
- Kammerer-Jacquet S.F., Cruzet L., Brunot A., Dagher J., Pladys A., Edeline J., Laguerre B., Peyronnet B., Mathieu R., Verhoest G., Patard J.J., Lespagnol A., Mosser J., Denis M., Messai Y., Gad-Lapiteau S., Chouaib S., Belaud-Rotureau M.A., Bensalah K., and Rioux-Leclercq N.** Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential. [2017] *International Journal of Cancer* (140) 1 : 142-148. Impact factor : 7.360
- Karkera J.D., Cardona G.M., Bell K., Gaffney D., Portale J.C., Santiago-Walker A., Moy C.H., King P., Sharp M., Bahleda R., Luo F.R., Alvarez J.D., Lorenzi M.V., and Platero S.J.** Oncogenic characterization and pharmacologic sensitivity of activating Fibroblast Growth Factor Receptor (FGFR) genetic alterations to the selective FGFR inhibitor erdafitinib. [2017] *Molecular Cancer Therapeutics* (16) 8 : 1717-1726. Impact factor : 5.365
- Kataoka K., Kinoshita T., Moehler M., Mauer M., Shitara K., Wagner A.D., Schrauwen S., Yoshikawa T., Roviello F., Tokunaga M., Boku N., Ducreux M., Terashima M., Lordick F., and EORTC GITCG Group and JCOG SCGC Group** Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. [2017] *Gastric Cancer* (20) 5 : 904-912. Impact factor : 5.045
- Ke L., Zhou H., Wang C., Xiong G., Xiang Y., Ling Y., Khabir A., Tsao G.S., Zeng Y., Zeng M., Busson P., Kieff E., Guo X., and Zhao B.** Nasopharyngeal carcinoma super-enhancer-driven ETV6 correlates with prognosis. [2017] *Proceedings of the National Academy of Sciences of the United States of America* (114) 36 : 9683-9688. Impact factor : 9.504
- Kepp O., Loos F., Liu P., and Kroemer G.** Extracellular nucleosides and nucleotides as immunomodulators. [2017] *Immunological reviews* (280) 1 : 83-92. Impact factor : 9.217
- Kieran M.W., Chisholm J., Casanova M., Brandes A.A., Aerts I., Bouffet E., Bailey S., Leary S., MacDonald T.J., Mechinaud F., Cohen K.J., Riccardi R., Mason W., Hargrave D., Kalambakas S., Deshpande P., Tai F., Hurh E., and Geoerger B.** Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. [2017] *Neuro-Oncology* (19) 11 : 1542-1552. Impact factor : 9.384
- Kitson S., Sivalingam V.N., Bolton J., McVey R., Nickkho-Amiry M., Powell M.E., Leary A., Nijman H.W., Nout R.A., Bosse T., Renehan A.G., Kitchener H.C., Edmondson R.J., and Crosbie E.J.** Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies. [2017] *Modern Pathology* (30) 3 : 459-468. Impact factor : 6.655
- Kizys M.M.L., Louzada R.A., Mitne-Neto M., Jara J.R., Furuzawa G.K., de Carvalho D.P., Dias-da-Silva M.R., Nesi-Franca S., Dupuy C., and Maciel R.M.B.** DUOX2 Mutations Are Associated With Congenital Hypothyroidism With Ectopic Thyroid Gland. [2017] *Journal of Clinical Endocrinology & Metabolism* (102) 11 : 4060-4071. Impact factor : 5.789
- Knigge U., Capdevila J., Bartsch D.K., Baudin E., Falkerby J., Kianmanesh R., Kos-Kudla B., Niederle B., Nieveen van Dijkum E., O'Toole D., Pascher A., Reed N., Sundin A., and Vullierme M.-P.** ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: Follow-Up and Documentation. [2017] *Neuroendocrinology* (105) 3 : 310-319. Impact factor : 5.024
- Kouidhi S., Elgaied A.B., and Chouaib S.** Impact of Metabolism on T-Cell Differentiation and Function and Cross Talk with Tumor Microenvironment. [2017] *Frontiers in Immunology* (8) : 270. Impact factor : 5.511
- Kroemer G.** Death, danger & immunity: Fundamental mechanisms linking pathogenic or iatrogenic cell death events to immune responses. [2017] *Immunological reviews* (280) 1 : 5-7. Impact factor : 9.217
- Lamartina L., Borget I., Mirghani H., Al Ghuzlan A., Berdelou A., Bidault F., Deandreis D., Baudin E., Travagli J.P., Schlumberger M., Hartl D.M., and Leboulleux S.** Surgery for neck recurrence of differentiated thyroid cancer: Outcomes and risk factors. [2017] *Journal of Clinical Endocrinology & Metabolism* (102) 3 : 1020-1031. Impact factor : 5.789
- Landmann E., Burkhardt B., Zimmermann M., Meyer U., Woessmann W., Klapper W., Wrobel G., Rosolen A., Pillon M., Escherich G., Attarbaschi A., Beishuizen A., Mellgren K., Wynn R., Ratei R., Plesa A., Schrappe M., Reiter A., Bergeron C., Patte C., and Bertrand Y.** Results and conclusions of the European Intergroup EURO-LB02 Trial in children and adolescents with lymphoblastic lymphoma. [2017] *Haematologica* (102) 12 : 2086-2096. Impact factor : 9.090
- Lassau N., Coiffier B., Favier L., Benatsou B., Bidault S., Girard E., Asselain B., Pitre-Champagnat S., and Koscielny S.** Study of inpatient variability and reproducibility of quantitative tumor perfusion parameters evaluated with dynamic contrast-enhanced ultrasonography. [2017] *Investigative Radiology* (52) 3 : 148-154. Impact factor : 6.224
- Lazarovici J., Terroir M., Arfi-Rouche J., Michot J.M., Mussot S., Florea V., Ghigna M.R., Dartigues P., Petrovanu C., Danu A., Ferme C., Ribrag V., and Ghez D.** Poor predictive value of positive interim FDG-PET/CT in primary mediastinal large B-cell lymphoma. [2017] *European Journal of Nuclear Medicine and Molecular Imaging* (44) 12 : 2018-2024. Impact factor : 7.704
- Le Burel S., Champiat S., Mateus C., Marabelle A., Michot J.M., Robert C., Belkhir R., Soria J.C., Laghouati S., Voisin A.L., Fain O., Mekinian A., Coutte L., Szwebel T.A., Dunoigeant L., Lioger B., Luxembourger C., Mariette X., and Lambotte O.** Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. [2017] *European Journal of Cancer* (82) : 34-44. Impact factor : 7.191
- Le Guellec S., Macagno N., Velasco V., Lamant L., Lae M., Filleron T., Malissen N., Cassagnau E., Terrier P., Chevreau C., Ranchere-Vince D., and Coindre J.M.** Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. [2017] *Modern Pathology* (30) 12 : 1677-1687. Impact factor : 6.655
- Lebeault M., Pinson S., Guillaud-Bataille M., Gimenez-Roqueplo A.P., Carrie A., Barbu V.D., Pigny P., Bezieau S., Rey J.M., Delvincourt C., Girard S., Veyrat-Durebex C., Saulnier P., Bouzamondo N., Chabbert M., Blin J., Mohamed A., Romanet P., Borson-Chazot F., Rohmer V., Barlier A., and Delphine M.P.** Nationwide French study of RET variants detected from 2003 to 2013 suggests a possible influence of polymorphisms as modifiers. [2017] *Thyroid* (27) 12 : 1511-1522. Impact factor : 7.557
- Lebellec L., Chauffert B., Blay J.Y., Le Cesne A., Chevreau C., Bompas E., Bertucci F., Cupissol D., Fabbro M., Saada-Bouزيد E., Duffaud F., Feuvret L., Bonneville-Levard A., Bay J.O., Vauleon E., Vinceneux A., Noel G., Penel N., and Mir O.** Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). [2017] *European Journal of Cancer* (79) : 119-128. Impact factor : 7.191

- Lemaitre C., Tsang J., Bireau C., Heidmann T., and Dewannieux M.** A human endogenous retrovirus-derived gene that can contribute to oncogenesis by activating the ERK pathway and inducing migration and invasion. [2017] *Plos Pathogens* (13) 6 : e1006451. Impact factor : 6.158
- Levi F., Karaboue A., Saffroy R., Desterke C., Boige V., Smith D., Hebbar M., Innominato P., Taieb J., Carvalho C., Guimbaud R., Focan C., Bouchahda M., Adam R., Ducreux M., Milano G., and Lemoine A.** Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer [European trial OPTILIV, NCT00852228]. [2017] *British Journal of Cancer* (117) 7 : 965-973. Impact factor : 5.922
- Levy A., Nigro G., Sansonetti P.J., and Deutsch E.** Candidate immune biomarkers for radioimmunotherapy. [2017] *Biochimica et biophysica acta* (1868) 1 : 58-68. Impact factor : 8.220
- Li S.X., Imamura F., Ye Z., Schulte M.B., Zheng J., Ardanaz E., Arriola L., Boeing H., Dow C., Fagherazzi G., Franks P.W., Agudo A., Grioni S., Kaaks R., Katzke V.A., Key T.J., Khaw K.T., Mancini F.R., Navarro C., Nilsson P.M., Onland-Moret N.C., Overvad K., Palli D., Panico S., Quiros J.R., Rolandsson O., Sacerdote C., Sanchez M.J., Slimani N., Stuijls I., Spijkerman A.M.W., Tjonneland A., Tumino R., Sharp S.J., Riboli E., Langenberg C., Scott R.A., Forouhi N.G., and Wareham N.J.** Interaction between genes and macronutrient intake on the risk of developing type 2 diabetes: Systematic review and findings from European Prospective Investigation into Cancer (EPIC)-InterAct. [2017] *American Journal of Clinical Nutrition* (106) 1 : 263-275. Impact factor : 6.549
- Loibl S., de la Pena L., Nekljudova V., Zardavas D., Michiels S., Denkert C., Rezaei M., Bermejo B., Untch M., Lee S.C., Turri S., Urban P., Kummel S., Steger G., Gombos A., Lux M., Piccart M.J., Von Minckwitz G., Baselga J., and Loi S.** Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). [2017] *European Journal of Cancer* (85) : 133-145. Impact factor : 7.191
- Loibl S., Turner N.C., Ro J., Cristofanilli M., Iwata H., Im S.A., Masuda N., Loi S., Andre F., Harbeck N., Verma S., Folklerd E., Theall K.P., Hoffman J., Zhang K., Bartlett C.H., and Dowsett M.** Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. [2017] *Oncologist* (22) 9 : 1028-1038. Impact factor : 5.306
- Lokerse W.J.M., Bolkestein M., Dalm S.U., Eggermont A.M.M., De Jong M., Grull H., and Koning G.A.** Comparing the therapeutic potential of thermosensitive liposomes and hyperthermia in two distinct subtypes of breast cancer. [2017] *Journal of Controlled Release* (258) : 34-42. Impact factor : 7.877
- Loriot Y., Pagliaro L., Flechon A., Mardiac J., Geoffrois L., Kerbrat P., Chevreau C., Delva R., Rolland F., Theodore C., Roubaud G., Gravis G., Eymard J.C., Malhaire J.P., Linassier C., Habibian M., Martin A.L., Journeau F., Reckova M., Logothetis C., Laplanche A., Le Teuff G., Culine S., and Fizazi K.** Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastases. [2017] *European Journal of Cancer* (87) : 140-146. Impact factor : 7.191
- Loriot Y., Fizazi K., De Bono J.S., Forer D., Hirmand M., and Scher H.I.** Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial. [2017] *Cancer* (123) 2 : 253-262. Impact factor : 6.537
- Lubin J.H., Adams M.J., Shore R., Holmberg E., Schneider A.B., Hawkins M.M., Robison L.L., Inskip P.D., Lundell M., Johansson R., Kleinerman R.A., De Vathaire F., Damber L., Sadetzki S., Tucker M., Sakata R., and Veiga L.H.S.** Thyroid cancer following childhood low-dose radiation exposure: A pooled analysis of nine cohorts. [2017] *Journal of Clinical Endocrinology & Metabolism* (102) 7 : 2575-2583. Impact factor : 5.789
- Lutz M.P., Zalberg J.R., Ducreux M., Aust D., Bruno M.J., Buchler M.W., Delpero J.R., Gloor B., Glynne-Jones R., Hartwig W., Huguet F., Laurent-Puig P., Lordick F., Maisonneuve P., Mayerle J., Martignoni M., Neoptolemos J., Rhim A.D., Schmie B.M., Seufferlein T., Werner J., Van Laethem J.L., and Otto F.** 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. [2017] *European Journal of Cancer* (79) : 41-49. Impact factor : 7.191
- MacNeill A.J., Miceli R., Strauss D.C., Bonvalot S., Hohenberger P., Van Coevorden F., Rutkowski P., Callegaro D., Hayes A.J., Honore C., Fairweather M., Cannell A., Jakob J., Haas R.L., Szacht M., Fiore M., Casali P.G., Pollock R.E., Raut C.P., Gronchi A., and Swallow C.J.** Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Trans-Atlantic RPS Working Group. [2017] *Cancer* (123) 11 : 1971-1978. Impact factor : 6.537
- Mahjoubi L., Gazzah A., Marabelle A., Le Roy Ladurie F., Lambotte O., Caramella C., Adam J., Besse B., and Soria J.C.** Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer. [2017] *European Journal of Cancer* (85) : 155-157. Impact factor : 7.191
- Maiuri L., Raia V., and Kroemer G.** Strategies for the etiological therapy of cystic fibrosis. [2017] *Cell Death and Differentiation* (24) 11 : 1825-1844. Impact factor : 8.000
- Majzner R.G., Simon J.S., Grosso J.F., Martinez D., Pawel B.R., Santi M., Merchant M.S., Goeger B., Hezam I., Marty V., Vielh P., Daugaard M., Sorensen P.H., Mackall C.L., and Maris J.M.** Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. [2017] *Cancer* (123) 19 : 3807-3815. Impact factor : 6.537
- Malka D., Rotolo F., and Boige V.** First-line treatment in metastatic colorectal cancer: Important or crucial? [2017] *European Journal of Cancer* (84) : 363-366. Impact factor : 7.191
- Marino P., Sfumato P., Joly F., Fizazi K., Oudard S., Culine S., Habibian M., Boher J.M., and Gravis G.** Q-TWIST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial. [2017] *European Journal of Cancer* (84) : 27-33. Impact factor : 7.191
- Massard C., Borget I., Farace F., Aspeslagh S., Le Deley M.C., Le Tourneau C., Bidard F.C., Pierga J.Y., Dieras V., Hofman P., Spano J.P., Ferte C., Lacroix L., and Soria J.C.** RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. [2017] *European Journal of Cancer* (83) : 185-193. Impact factor : 7.191
- Massard C., Chi K.N., Castellano D., de Bono J., Gravis G., Dirix L., Machiels J.P., Mita A., Mellado B., Turri S., Maier J., Csonka D., Chakravarty A., and Fizazi K.** Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44]. [2017] *European Journal of Cancer* (81) : 242. Impact factor : 7.191
- Massard C., Chi K.N., Castellano D., De Bono J., Gravis G., Dirix L., Machiels J.P., Mita A., Gonzalez B.M., Turri S., Maier J., Csonka D., Chakravarty A., and Fizazi K.** Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. [2017] *European Journal of Cancer* (76) : 36-44. Impact factor : 7.191
- Matejic M., de Batlle J., Ricci C., Biessy C., Perrier F., Huybrechts I., Weiderpass E., Ruault B.M., Cadeau C., His M., Cox D.G., Boeing H., Fortner R.T., Kaaks R., Lagiou P., Trichopoulou A., Benetou V., Tumino R., Panico S., Sieri S., Palli D., Ricceri F., Bueno-De-Mesquita H.B., Skeie G., Amiano P., Sanchez M.J., Chirlaque M.D., Barricarte A., Quiros J.R., Buckland G., Van Gils C.H., Peeters P.H., Key T.J., Riboli E., Gylling B.,**

- Zeleniuch-Jacquotte A., Gunter M.J., Romieu I., and Chajes V.** Biomarkers of folate and vitamin B12 and breast cancer risk: Report from the EPIC cohort. [2017] *International Journal of Cancer* (140) 6 : 1246-1259. Impact factor : 7.360
- Matias M., Le Teuff G., Albiges L., Guida A., Brard C., Bacciarelo G., Loriot Y., Massard C., Lassau N., Fizazi K., and Escudier B.** Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. [2017] *European Journal of Cancer* (79) : 185-192. Impact factor : 7.191
- Mazeron R., Rivin del Campo E., Haie-Meder C., and Chargari C.** In Regard to Swanick et al. [2017] *International Journal of Radiation Oncology Biology Physics* (97) 3 : 638. Impact factor : 5.554
- Mazza C., Escudier B., and Albiges L.** Nivolumab in renal cell carcinoma: Latest evidence and clinical potential. [2017] *Therapeutic Advances in Medical Oncology* (9) 3 : 171-181. Impact factor : 6.238
- Messaoudene M., Frazao A., Gavlovsky P.J., Toubert A., Dulphy N., and Caignard A.** Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers. [2017] *Frontiers in Immunology* (8) : 683. Impact factor : 5.511
- Mgrditchian T., Arakelian T., Paggetti J., Noman M.Z., Viry E., Moussay E., Van Moer K., Kreis S., Guerin C., Buart S., Robert C., Borg C., Vielh P., Chouaib S., Berchem G., and Janji B.** Targeting autophagy inhibits melanoma growth by enhancing NK cells infiltration in a CCL5-dependent manner. [2017] *Proceedings of the National Academy of Sciences of the United States of America* (114) 44 : E9271-E9279. Impact factor : 9.504
- Michallet A.S., Campidelli A., Lequeu H., Dilhuyd M.S., Tournilhac O., Fornecker L.M., Dupuis J., Cymbalista F., de Guibert S., Delmer A., Vitque J.P., Ghez D., Leblond V., Subtil F., Feugier P., and Ysebaert L.** Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group. [2017] *American Journal of Hematology* (92) 6 : E105-E107. Impact factor : 5.303
- Michot J.M., Lazarovici J., Ghez D., Danu A., Ferme C., Bigorgne A., Ribrag V., Marabelle A., and Aspeslagh S.** Challenges and perspectives in the immunotherapy of Hodgkin lymphoma. [2017] *European Journal of Cancer* (85) : 67-77. Impact factor : 7.191
- Michot J.M., Vargaftig J., Leduc C., Quere G., Burrioni B., Lazarovici J., Champiat S., Ribrag V., and Lambotte O.** Immune-related bone marrow failure following anti-PD1 therapy. [2017] *European Journal of Cancer* (80) : 1-4. Impact factor : 7.191
- Midttun O., Theofylaktopoulou D., McCann A., Fanidi A., Muller D.C., Meyer K., Ulvik A., Zheng W., Shu X.O., Xiang Y.B., Prentice R., Thomson C.A., Pettinger M., Giles G.G., Hodge A., Cai Q., Blot W.J., Wu J., Johansson M., Hultdin J., Grankvist K., Stevens V.L., McCullough M.L., Weinstein S.J., Albanes D., Langhammer A., Hveem K., Naess M., Sesso H.D., Gaziano J.M., Buring J.E., Lee I.M., Severi G., Zhang X., Han J., Stampfer M.J., Smith-Warner S.A., Zeleniuch-Jacquotte A., Le M.L., Yuan J.M., Butler L.M., Koh W.P., Wang R., Gao Y.T., Ericson U., Sonestedt E., Ziegler R.G., Freedman N.D., Visvanathan K., Jones M.R., Relton C., Brennan P., Johansson M., and Ueland P.M.** Circulating concentrations of biomarkers and metabolites related to vitamin status, one-carbon and the kynurenine pathways in US, Nordic, Asian, and Australian populations. [2017] *American Journal of Clinical Nutrition* (105) 6 : 1314-1326. Impact factor : 6.549
- Milne R.L., Fletcher A.S., MacInnis R.J., Hodge A.M., Hopkins A.H., Bassett J.K., Bruinsma F.J., Lynch B.M., Dugue P.A., Jayasekara H., Brinkman M.T., Popowski L.V., Baglietto L., Severi G., O'Dea K., Hopper J.L., Southey M.C., English D.R., and Giles G.G.** Cohort Profile: The Melbourne Collaborative Cohort Study (Health 2020). [2017] *International journal of epidemiology* (46) 6 : 1757-1757i. Impact factor : 8.360
- Mirghani H., Jung A.C., and Fakhry C.** Primary, secondary and tertiary prevention of human papillomavirus-driven head and neck cancers. [2017] *European Journal of Cancer* (78) : 105-115. Impact factor : 7.191
- Mirouse A., Vignon P., Piron P., Robert R., Papazian L., Geri G., Blanc P., Guitton C., Guerin C., Bige N., Rabbat A., Lefebvre A., Razazi K., Fartoukh M., Mariotte E., Bouadma L., Ricard J.D., Seguin A., Souweine B., Moreau A.S., Faguer S., Mari A., Mayaux J., Schneider F., Stoclin A., Perez P., Maizel J., Lafon C., Ganster F., Argaud L., Girault C., Barbier F., Lecuyer L., Lambert J., and Canet E.** Severe varicella-zoster virus pneumonia: a multicenter cohort study. [2017] *Critical Care* (21) 1 : 137. Impact factor : 6.425
- Molina-Montes E., Sanchez M.J., Buckland G., Bueno-De-Mesquita H.B., Weiderpass E., Amiano P., Wark P.A., Kuhn T., Katzke V., Huerta J.M., Ardanaz E., Quiros J.R., Affret A., His M., Boutron-Ruault M.C., Peeters P.H., Ye W., Sund M., Boeing H., Iqbal K., Ohlsson B., Sonestedt E., Tjonneland A., Petersen K.E.N., Travis R.C., Skeie G., Agnoli C., Panico S., Palli D., Tumino R., Sacerdote C., Freisling H., Huybrechts I., Overvad K., Trichopoulou A., Bamia C., Vasilopoulou E., Wareham N., Khaw K.T., Cross A.J., Ward H.A., Riboli E., and Duell E.J.** Mediterranean diet and risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition cohort. [2017] *British Journal of Cancer* (116) 6 : 811-820. Impact factor : 5.922
- Motzer R.J., Escudier B., Gannon A., and Fliglin R.A.** Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. [2017] *Oncologist* (22) 1 : 41-52. Impact factor : 5.306
- Moya A., Larochette N., Paquet J., Deschepper M., Bendsidhoum M., Izzo V., Kroemer G., Petite H., and Logeart-Avramoglou D.** Quiescence Preconditioned Human Multipotent Stromal Cells Adopt a Metabolic Profile Favorable for Enhanced Survival under Ischemia. [2017] *Stem Cells* (35) 1 : 181-196. Impact factor : 5.587
- Munford V., Castro L.P., Souto R., Lerner L.K., Vilar J.B., Quayle C., Asif H., Schuch A.P., de Souza T.A., Ienne S., Alves F.I., Moura L.M., Galante P.A., Camargo A.A., Liboredo R., Pena S.D., Sarasin A., Chaibub S.C., and Menck C.F.** A genetic cluster of xeroderma pigmentosum variant patients with two different founder mutations. [2017] *British Journal of Dermatology* (176) 5 : 1270-1278. Impact factor : 6.129
- Musolino A., Campone M., Neven P., Denduluri N., Barrios C.H., Cortes J., Blackwell K., Soliman H., Kahan Z., Bonnefoi H., Squires M., Zhang Y., Deudon S., Shi M.M., and Andre F.** Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+. [2017] *Breast Cancer Research* (19) 1 : 18. Impact factor : 6.142
- Mynarek M., Pizer B., Dufour C., van Vuurden D., Garami M., Massimino M., Fangusaro J., Davidson T., Gil-da-Costa M.J., Sterba J., Benesch M., Gerber N., Juhnke B.O., Kwicien R., Pietsch T., Kool M., Clifford S., Ellison D.W., Giangaspero F., Wesseling P., Gilles F., Gottardo N., Finlay J.L., Rutkowski S., and von Hoff K.** Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: Analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data. [2017] *Neuro-Oncology* (19) 4 : 576-585. Impact factor : 9.384
- Najem A., Krayem M., Sales F., Hussein N., Badran B., Robert C., Awada A., Journe F., and Ghanem G.E.** P53 and MTF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. [2017] *European Journal of Cancer* (83) : 154-165. Impact factor : 7.191
- Nebot-Bral L., Brandao D., Verlingue L., Rouleau E., Caron O., Despras E., El-Dakdouki Y., Champiat S., Aoufouchi S., Leary A., Marabelle A., Malka D., Chaput N., and Kannouche P.L.** Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. [2017] *European Journal of Cancer* (84) : 290-303. Impact factor : 7.191

- Nehlig A., Molina A., Rodrigues-Ferreira S., Honore S., and Nahmias C.** Regulation of end-binding protein EB1 in the control of microtubule dynamics. [2017] *Cellular and Molecular Life Sciences* (74) 13 : 2381-2393. Impact factor : 6.710
- Nimptsch K., Song M., Aleksandrova K., Katsoulis M., Freisling H., Jenab M., Gunter M.J., Tsilidis K.K., Weiderpass E., Bueno-De-Mesquita H.B., Chong D.Q., Jensen M.K., Wu C., Overvad K., Kuhn T., Barndahl M., Melander O., Jirstrom K., Peeters P.H., Sieri S., Panico S., Cross A.J., Riboli E., van Guelpen B., Myte R., Huerta J.M., Rodriguez-Barranco M., Quiros J.R., Dorronsoro M., Tjonneland A., Olsen A., Travis R., Boutron-Ruault M.C., Caronnel F., Severi G., Bonet C., Palli D., Janke J., Lee Y.A., Boeing H., Giovannucci E.L., Ogino S., Fuchs C.S., Rimm E., Wu K., Chan A.T., and Pischon T.** Genetic variation in the ADIPOQ gene, adiponectin concentrations and risk of colorectal cancer: a Mendelian Randomization analysis using data from three large cohort studies. [2017] *European Journal of Epidemiology* (32) 5 : 419-430. Impact factor : 7.023
- Noman M.Z., Janji B., Abdou A., Hasmim M., Terry S., Tan T.Z., Mami-Chouaib F., Thiery J.P., and Chouaib S.** The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. [2017] *Oncolmmunology* (6) 1 : e1263412. Impact factor : 5.503
- Oberg K., Couvelard A., Delle Fave G., Gross D., Grossman A., Jensen R.T., Pape U.F., Perren A., Rindi G., Ruzsniewski P., Scoazec J.Y., Welin S., Wiedenmann B., and Ferone D.** ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. [2017] *Neuroendocrinology* (105) 3 : 201-211. Impact factor : 5.024
- Omer N., Le Deley M.C., Piperno-Neumann S., Marec-Berard P., Italiano A., Corradini N., Bellera C., Brugieres L., and Gaspar N.** Phase-II trials in osteosarcoma recurrences: A systematic review of past experience. [2017] *European Journal of Cancer* (75) : 98-108. Impact factor : 7.191
- Ose J., Poole E.M., Schock H., Lehtinen M., Arslan A.A., Zeleniuch-Jacquotte A., Visvanathan K., Helzlsouer K., Buring J.E., Lee I.M., Tjonneland A., Dossus L., Trichopoulos A., Masala G., Onland-Moret N.C., Weiderpass E., Duell E.J., Idahl A., Travis R.C., Rinaldi S., Merritt M.A., Trabert B., Wentzensen N., Tworoger S.S., Kaaks R., and Fortner R.T.** Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium. [2017] *Cancer Research* (77) 14 : 3951-3960. Impact factor : 9.130
- Ou D., Adam J., Garberis I., Blanchard P., Nguyen F., Levy A., Casiraghi O., Gorphe P., Breuskin I., Janot F., Temam S., Scoazec J.Y., Deutsch E., and Tao Y.** Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy. [2017] *Oncolmmunology* (6) 9 : e1341030. Impact factor : 5.503
- Oude Ophuis C.M.C., van Akkooi A.C.J., Rutkowski P., Powell W.E.M., Robert C., Testori A., van Leeuwen B.L., Siegel P., Eggermont A.M.M., Verhoef C., and Grunhagen D.J.** Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma. [2017] *British Journal of Surgery* (104) 6 : 726-733. Impact factor : 5.433
- Pages A., Foulon S., Zou Z., Lacroix L., Lemare F., de Baere T., Massard C., Soria J.C., and Bonastre J.** The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial. [2017] *Genetics in Medicine* (19) 6 : 683-690. Impact factor : 9.937
- Paillet E., Oulhen M., Borget I., Remon J., Ross K., Auger N., Billiot F., Ngo Camus M., Commo F., Lindsay C.R., Planchard D., Soria J.-C., Besse B., and Farace F.** Circulating tumor cells with aberrant ALK copy number predict progression-free survival during crizotinib treatment in ALK-rearranged non-small cell lung cancer patients. [2017] *Cancer Research* (77) 9 : 2222-2230. Impact factor : 9.130
- Partelli S., Bartsch D.K., Capdevila J., Chen J., Knigge U., Niederle B., van Dijkum E.J.M.N., Pape U.F., Pascher A., Ramage J., Reed N., Ruzsniewski P., Scoazec J.Y., Toumpanakis C., Kianmanesh R., and Falconi M.** ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. [2017] *Neuroendocrinology* (105) 3 : 255-265. Impact factor : 5.024
- Patnaik M.M., Timm M.M., Vallapureddy R., Lasho T.L., Ketterling R.P., Gangat N., Shi M., Tefferi A., Solary E., Reichard K.K., and Jevremovic D.** Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. [2017] *Blood cancer journal* (7) 7 : e584. Impact factor : 8.125
- Paviglianiti A., Ruggeri A., Volt F., Sanz G., Milpied N., Furst S., Esquirol A., Arcese W., Picardi A., Ferra C., Ifrah N., Bourhis J.H., Raj K., von dem Borne P.A., Sica S., Menard A.L., Bloor A., Kenzey C., Gluckman E., and Rocha V.** Evaluation of a disease risk index for adult patients undergoing umbilical cord blood transplantation for haematological malignancies. [2017] *British Journal of Haematology* (179) 5 : 790-801. Impact factor : 5.128
- Penel N., Le Cesne A., Bonvalot S., Giraud A., Bompas E., Rios M., Salas S., Isambert N., Boudou-Rouquette P., Honore C., Italiano A., Ray-Coquard I., Piperno-Neumann S., Gouin F., Bertucci F., Ryckewaert T., Kurtz J.E., Ducimetiere F., Coindre J.M., and Blay J.Y.** Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. [2017] *European Journal of Cancer* (83) : 125-131. Impact factor : 7.191
- Perez-Cornago A., Appleby P.N., Tipper S., Key T.J., Allen N.E., Nieters A., Vermeulen R., Roulland S., Casabonne D., Kaaks R., Fortner R.T., Boeing H., Trichopolou A., La V.C., Klinaki E., Hansen L., Tjonneland A., Bonnet F., Fagherazzi G., Boutron-Ruault M.C., Pala V., Masala G., Sacerdote C., Peeters P.H., Bueno-De-Mesquita H.B., Weiderpass E., Dorronsoro M., Quiros J.R., Barricarte A., Gavrila D., Agudo A., Borgquist S., Rosendahl A.H., Melin B., Wareham N., Khaw K.T., Gunter M., Riboli E., Vineis P., and Travis R.C.** Prediagnostic circulating concentrations of plasma insulin-like growth factor-I and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition. [2017] *International Journal of Cancer* (140) 5 : 1111-1118. Impact factor : 7.360
- Pernot S., Badoual C., Terme M., Castan F., Cazes A., Bouche O., Bennouna J., Francois E., Ghiringelli F., De La Fouchardiere C., Samalin E., Bacht J.B., Borg C., Ducreux M., Marcheteau E., Stanbury T., Gourgou S., Malka D., and Taieb J.** Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. [2017] *European Journal of Cancer* (79) : 15-22. Impact factor : 7.191
- Perren A., Couvelard A., Scoazec J.-Y., Costa F., Borbath I., Delle Fave G., Gorbounova V., Gross D., Grossma A., Jense R.T., Kulke M., Oberg K., Rindi G., Sorbye H., and Welin S.** ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. [2017] *Neuroendocrinology* (105) 3 : 196-200. Impact factor : 5.024
- Petrella T.M., Robert C., Richtig E., Miller W.H., Jr., Masucci G.V., Walpole E., Lebbe C., Steven N., Middleton M.R., Hille D., Zhou W., Ibrahim N., and Cebon J.** Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. [2017] *European Journal of Cancer* (86) : 115-124. Impact factor : 7.191
- Pezzi T.A., Mohamed A.S., Sheu T., Blanchard P., Sandulache V.C., Lai S.Y., Cabanillas M.E., Williams M.D., Pezzi C.M., Lu C., Garden A.S., Morrison W.H., Rosenthal D.I., Fuller C.D., and Gunn G.B.** Radiation therapy dose is associated with improved

- survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. [2017] *Cancer* (123) 9 : 1653-1661. Impact factor : 6.537
- Pierini S., Perales-Linares R., Uribe-Herranz M., Pol J.G., Zitvogel L., Kroemer G., Facciabene A., and Galluzzi L.** Trial watch: DNA-based vaccines for oncological indications. [2017] *Oncolmmunology* (6) 12 : e1398878. Impact factor : 5.503
- Pitt J.M., Vetizou M., Gomperts B., I, Lepage P., Chamaillard M., and Zitvogel L.** Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. [2017] *Oncolmmunology* (6) 1 : e1132137. Impact factor : 5.503
- Pivot X., Fumoleau P., Pierga J.Y., Delaloge S., Bonnefoi H., Bachelot T., Jouannaud C., Bourgeois H., Rios M., Soulie P., Jacquin J.P., Lavau-Denes S., Kerbrat P., Cox D., Faure-Mercier C., Pauporte I., Gligorov J., Curtit E., Henriques J., Paget-Bailly S., and Romieu G.** Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohort. [2017] *European Journal of Cancer* (81) : 151-160. Impact factor : 7.191
- Poggi M., Canault M., Favier M., Turro E., Saultier P., Ghalloussi D., Baccini V., Vidal L., Mezzapesa A., Chelghoum N., Mohand-Oumoussa B., Falaise C.L., Favier R., Ouwehand W.H., Fiore M., Peiretti F., Morange P.E., Saut N., Bernot D., Greinacher A., Nurden A.T., Nurden P., Freson K., Tregouet D.A., Raslova H., and Alessi M.C.** Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors. [2017] *Haematologica* (102) 2 : 282-294. Impact factor : 9.090
- Pradere P., Michot J.M., Champiat S., Danlos F.X., Marabelle A., Lambotte O., Albiges L., and Le Pavec J.** Allergic broncho-pulmonary aspergillosis following treatment with an anti-programmed cell death protein 1 monoclonal antibody therapy. [2017] *European Journal of Cancer* (75) : 308-309. Impact factor : 7.191
- Puzanov I., Diab A., Abdallah K., Bingham C.O., III, Brogdon C., Dadu R., Hamad L., Kim S., Lacouture M.E., LeBoeuf N.R., Lenihan D., Onofrei C., Shannon V., Sharma R., Silk A.W., Skondra D., Suarez-Almazor M.E., Wang Y., Wiley K., Kaufman H.L., Ernstoff M.S., Anderson J., Lehman K., Reshef D., Saylor A., Turner M., Waxman I., Arrindell D., Andrews S., Ballesteros J., Boyer J., Cotarla I., Dawson M., Goswami T., Hayreh V., Holmes W., Rasheed Z., Sarkeshik M., Schreiber J., Shafer-Weaver K., Chen D., Ley-Acosta S., Chonzi D., Go W., Cunha R., Gulley J.L., Wood L., Davies M., Dicker A., Eifler L., Gregory N., Ferguson A., Ferlini C., Frankel S., Gochett C., Goldberg J., Patel K., Wariabharaj D., Goncalves P., Helie N., Hsu J.Y., Ibrahim R., Larocca C., Lambotte O., Luke J., McClure J., Michelon E., Nakamura M., Piperdi B., Riemer J., Robert C., Sharfman W., Sharon E., Sherry R., Simonson C., Thomas C., Trehu E., Thompson J.A., Tresnan D., Zhang L., and Zheng P.** Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [2017] *Journal for Immunotherapy of Cancer* (5) 1 : 95. Impact factor : 8.374
- Ray-Coquard I., Lauraine E.P., Le Cesne A., Pautier P., Lavenue M.C.V., Trama A., Casali P., Coindre J.M., and Blay J.Y.** Improving treatment results with reference centres for rare cancers: where do we stand? [2017] *European Journal of Cancer* (77) : 90-98. Impact factor : 7.191
- Reguart N., Teixido C., Gimenez-Capitan A., Pare L., Galvan P., Viteri S., Rodriguez S., Peg V., Aldeguer E., Vinolas N., Remon J., Karachaliou N., Conde E., Lopez-Rios F., Nadal E., Merkelbach-Bruse S., Buttner R., Rosell R., Molina-Vila M.A., and Prat A.** Identification of ALK, ROS1, and RET fusions by a multiplexed mRNA-based assay in formalin-fixed, paraffin-embedded samples from advanced non-small-cell lung cancer patients. [2017] *Clinical Chemistry* (63) 3 : 751-760. Impact factor : 8.636
- Remon J., Besse B., and Soria J.C.** Erratum to: Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? [2017] *Bmc Medicine* (15) 1 : 82. Impact factor : 9.088
- Remon J., Besse B., and Soria J.C.** Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? [2017] *Bmc Medicine* (15) 1 : 55. Impact factor : 9.088
- Remon J., Le Rhun E., and Besse B.** Leptomeningeal carcinomatosis in non-small cell lung cancer patients: A continuing challenge in the personalized treatment era. [2017] *Cancer Treatment Reviews* (53) : 128-137. Impact factor : 8.122
- Renda F., Pellacani C., Strunov A., Bucciarelli E., Naim V., Bosso G., Kiseleva E., Bonaccorsi S., Sharp D.J., Khodjakov A., Gatti M., and Somma M.P.** The Drosophila orthologue of the INT6 onco-protein regulates mitotic microtubule growth and kinetochore structure. [2017] *PLoS Genetics* (13) 5 : e1006784. Impact factor : 5.540
- Ribrig V., Kim W.S., Bouabdallah R., Lim S.T., Coiffier B., Illes A., Lemieux B., Dyer M.J.S., Offner F., Felloussi Z., Kloos I., Luan Y., Vezen R., Graef T., and Morschhauser F.** Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: Results of a phase II study. [2017] *Haematologica* (102) 5 : 903-909. Impact factor : 9.090
- Riet F.G., Fayard F., Arriagada R., Santos M.A., Bourgier C., Ferchiou M., Heymann S., Delaloge S., Mazouni C., Dunant A., and Rivera S.** Preoperative radiotherapy in breast cancer patients: 32 years of follow-up. [2017] *European Journal of Cancer* (76) : 45-51. Impact factor : 7.191
- Rodon J., Postel-Vinay S., Hollebecque A., Nuciforo P., Azaro A., Cattani V., Marfai L., Sudey I., Brendel K., Delmas A., Malasse S., and Soria J.C.** First-in-human phase I study of oral S49076, a unique MET/AXL/FGFR inhibitor, in advanced solid tumours. [2017] *European Journal of Cancer* (81) : 142-150. Impact factor : 7.191
- Romieu I., Ferrari P., Chajes V., de Battlle J., Biessy C., Scoccianti C., Dossus L., Boutron M.C., Bastide N., Overvad K., Olsen A., Tjonneland A., Kaaks R., Boeing H., Trichopoulos A., Lagiou P., Trichopoulos D., Palli D., Sieri S., Tumino R., Vineis P., Panico S., Bueno-De-Mesquita H.B., Gils C.H., Peeters P.H., Lund E., Skeie G., Weiderpass E., Quiros J.R., Chirlaque M.D., Ardanaz E., Sanchez M.J., Duell E.J., Amiano E.P., Borgquist S., Hallmans G., Johansson I., Nilsson L.M., Khaw K.T., Wareham N., Key T.J., Travis R.C., Murphy N., Wark P.A., and Riboli E.** Fiber intake modulates the association of alcohol intake with breast cancer. [2017] *International Journal of Cancer* (140) 2 : 316-321. Impact factor : 7.360
- Roport S., Coriat R., Verret B., Perret A., Lucibello F., Chamseddine A.N., Armand J.P., Paci A., and Mir O.** Colchicine is an active treatment for everolimus-induced oral ulcers. [2017] *European Journal of Cancer* (87) : 209-211. Impact factor : 7.191
- Routy B., Letendre C., Enot D., Chenard-Poirier M., Mehraj V., Charbonneau Seguin N., Guenda K., Gagnon K., Woerther P.L., Ghez D., and Lachance S.** The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation. [2017] *Oncolmmunology* (6) 1 : e1258506. Impact factor : 5.503
- Rouzier R., Uzan C., Rousseau A., Guillot E., Zilberman S., Meyer C., Estevez P., Dupre P.F., Kere D., Doridot V., D'Halluin G., Fritel X., Pouget N., Jankowski C., Mazouni C., Simon T., and Coutant C.** Multicenter prospective evaluation of the reliability of the combined use of two models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: The MSKCC nomogram and the Tenon score. Results of the NOTEGS study. [2017] *British Journal of Cancer* (116) 9 : 1135-1140. Impact factor : 5.922

- Roviello G., Andre F., Venturini S., Pistilli B., Curigliano G., Cristofanilli M., Rosellini P., and Generali D.** Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. [2017] *European Journal of Cancer* (86) : 257-265. Impact factor : 7.191
- Rusakiewicz S., Perier A., Semeraro M., Pitt J.M., von Strandmann E.P., Reiners K.S., Aspeslagh S., Piperoglou C., Vely F., Ivagnes A., Jegou S., Halama N., Chaigneau L., Validire P., Christidis C., Perniceni T., Landi B., Berger A., Isambert N., Domont J., Bonvalot S., Terrier P., Adam J., Coindre J.M., Emile J.F., Poirier-Colame V., Chaba K., Rocha B., Caignard A., Toubert A., Enot D., Koch J., Marabelle A., Lambert M., Caillat-Zucman S., Leyvraz S., Auclair C., Vivier E., Eggermont A., Borg C., Blay J.Y., Le Cesne A., Mir O., and Zitvogel L.** NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. [2017] *Oncology* (6) 1 : e1137418. Impact factor : 5.503
- Rydzewska L.H.M., Burdett S., Vale C.L., Clarke N.W., Fizazi K., Kheoh T., Mason M.D., Miladinovic B., James N.D., Parmar M.K.B., Spears M.R., Sweeney C.J., Sydes M.R., Tran N., and Tierney J.F.** Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. [2017] *European Journal of Cancer* (84) : 88-101. Impact factor : 7.191
- Salgado R., Moore H., Martens J.W.M., Lively T., Malik S., McDermott U., Michiels S., Moscow J.A., Tejpar S., McKee T., and Lacombe D.** Societal challenges of precision medicine: Bringing order to chaos. [2017] *European Journal of Cancer* (84) : 325-334. Impact factor : 7.191
- Sarkozy C., Molina T., Ghesquieres H., Michallet A.S., Dupuis J., Damotte D., Morsschauser F., Parrens M., Martin L., Dartigues P., Stamatoullas A., Hirsch P., Fabiani B., Bouabdallah K., da Silva M.G., Maerevoet M., Laurent C., Coiffier B., Salles G., and Traverse-Glehen A.** Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association. [2017] *Haematologica* (102) 1 : 150-159. Impact factor : 9.090
- Savina M., Le Cesne A., Blay J.Y., Ray-Coquard I., Mir O., Toulmonde M., Cousin S., Terrier P., Ranchere-Vincent D., Meeus P., Stoockle E., Honore C., Sargos P., Sunyach M.P., Le Pechoux C., Giraud A., Bellera C., Le Loarer F., and Italiano A.** Patterns of care and outcomes of patients with METastatic soft tissue SARcoma in a real-life setting: The METASARC observational study. [2017] *Bmc Medicine* (15) 1 : 78. Impact factor : 9.088
- Schadendorf D., Long G.V., Stroiakovski D., Karaszewska B., Hauschild A., Levchenko E., Chiarion-Sileni V., Schachter J., Garbe C., Dutriaux C., Gogas H., Mandala M., Haanen J.B.A.G., Lebbe C., Mackiewicz A., Rutkowski P., Grob J.J., Nathan P., Ribas A., Davies M.A., Zhang Y., Kaper M., Mookerjee B., Legos J.J., Flaherty K.T., and Robert C.** Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. [2017] *European Journal of Cancer* (82) : 45-55. Impact factor : 7.191
- Schoffski P., Wozniak A., Escudier B., Rutkowski P., Anthony A., Bauer S., Suflarsky J., van Herpen C., Lindner L.H., Grunwald V., Zakotnik B., Lerut E., Debiec-Rychter M., Marreaud S., Lia M., Raveloarivahy T., Collette S., and Albiges L.** Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. [2017] *European Journal of Cancer* (87) : 147-163. Impact factor : 7.191
- Scoazec J.Y., Couvelard A., Monges G., Guyetant S., Bisot-Locard S., Parot X., and Lepage C.** Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey Among French Pathologists (the PRONET Study). [2017] *Neuroendocrinology* (105) 1 : 67-76. Impact factor : 5.024
- Shankar A.G., Roques G., Kirkwood A.A., Lambilliotte A., Freund K., Leblanc T., Hayward J., Abbou S., Ramsay A.D., Schmitt C., Gorde-Grosjean S., Pacquement H., Haouy S., Boudjemaa S., Aladjidi N., Hall G.W., and Landman-Parker J.** Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups. [2017] *British Journal of Haematology* (177) 1 : 106-115. Impact factor : 5.128
- Sixt B.S. and Kroemer G.** Chlamydia Anti-apoptosis - A By-product of Metabolic Reprogramming? [2017] *EBioMedicine* (23) : 2-3. Impact factor : 6.183
- Solier S., Fontenay M., Vainchenker W., Droin N., and Solary E.** Non-apoptotic functions of caspases in myeloid cell differentiation. [2017] *Cell Death and Differentiation* (24) 8 : 1337-1347. Impact factor : 8.000
- Soria J.C., Adjei A.A., Bahleda R., Besse B., Ferte C., Planchard D., Zhou J., Ware J., Morrissey K., Shankar G., Lin W., Schutzman J.L., Dy G.K., and Groen H.J.M.** A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer. [2017] *European Journal of Cancer* (86) : 186-196. Impact factor : 7.191
- Stepien M., Hughes D.J., Hybsier S., Bamia C., Tjonneland A., Overvad K., Affret A., His M., Boutron-Ruault M.C., Katzke V., Kuhn T., Aleksandrova K., Trichopoulou A., Lagiou P., Orfanos P., Palli D., Sieri S., Tumino R., Ricceri F., Panico S., Bueno-De-Mesquita H.B., Peeters P.H., Weiderpass E., Lasheras C., Bonet B.C., Molina-Portillo E., Dorronsoro B., Huerta J.M., Barricarte A., Ohlsson B., Sjoberg K., Werner M., Shungin D., Wareham N., Khaw K.T., Travis R.C., Freisling H., Cross A.J., Schomburg L., and Jenab M.** Circulating copper and zinc levels and risk of hepatobiliary cancers in Europeans. [2017] *British Journal of Cancer* (116) 5 : 688-696. Impact factor : 5.922
- Stepien M., Jenab M., Freisling H., Becker N.P., Czuban M., Tjonneland A., Olsen A., Overvad K., Boutron-Ruault M.C., Mancini F.R., Savoye I., Katzke V., Kuhn T., Boeing H., Iqbal K., Trichopoulou A., Bamia C., Orfanos P., Palli D., Sieri S., Tumino R., Naccarati A., Panico S., Bueno-de-Mesquita H.B.A., Peeters P.H., Weiderpass E., Merino S., Jakszyn P., Sanchez M.J., Dorronsoro M., Huerta J.M., Barricarte A., Boden S., van Guelpen B., Wareham N., Khaw K.T., Bradbury K.E., Cross A.J., Schomburg L., and Hughes D.J.** Pre-diagnostic copper and zinc biomarkers and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. [2017] *Carcinogenesis* (38) 7 : 699-707. Impact factor : 5.072
- Stoll G., Ma Y., Yang H., Kepp O., Zitvogel L., and Kroemer G.** Pro-necrotic molecules impact local immunosurveillance in human breast cancer. [2017] *Oncology* (6) 4 : e1299302. Impact factor : 5.503
- Stoll G., Caron B., Viara E., Dugourd A., Zinovyev A., Naldi A., Kroemer G., Barillot E., and Calzone L.** MaBoSS 2.0: an environment for stochastic Boolean modeling. [2017] *Bioinformatics* (33) 14 : 2226-2228. Impact factor : 5.481
- Su S.C., Mockenhaupt M., Wolkenstein P., Dunant A., Le Gouvello S., Chen C.B., Chosidow O., Valeyrie-Allanore L., Bellon T., Sekula P., Wang C.W., Schumacher M., Kardaun S.H., Hung S.I., Roujeau J.C., and Chung W.H.** Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. [2017] *Journal of Investigative Dermatology* (137) 5 : 1065-1073. Impact factor : 6.448
- Sullivan I., Le Teuff G., Guigay J., Caramella C., Berdelou A., Leboulleux S., Deandreis D., Hadoux J., Ducreux M., Duvallard P., Adam J., Scoazec J.Y., Baudin E., and Planchard D.** Antitumor activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. [2017] *European Journal of Cancer* (75) : 259-267. Impact factor : 7.191

- Sun R., Danlos F.X., Ammari S., Louvel G., Dhermain F., Champiat S., Lambotte O., and Deutsch E.** Anti-PD-1 Vasculitis of the central nervous system or radionecrosis? [2017] *Journal for Immunotherapy of Cancer* (5) 1 : 96. Impact factor : 8.374
- Sun R., Champiat S., Dercle L., Aspeslagh S., Castanon E., Limkin E.J., Baldini C., Postel-Vinay S., Hollebecque A., Massard C., Ammari S., Deutsch E., Soria J.C., Marabelle A., and Ferte C.** Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). [2017] *European Journal of Cancer* (84) : 202-211. Impact factor : 7.191
- Sun Y., Li T., Xie C., Xu Y., Zhou K., Rodriguez J., Han W., Wang X., Kroemer G., Modjtahedi N., Blomgren K., and Zhu C.** Haploinsufficiency in the mitochondrial protein CHCHD4 reduces brain injury in a mouse model of neonatal hypoxia-ischemia. [2017] *Cell Death & Disease* (8) 5 : e2781. Impact factor : 5.638
- Sundin A., Arnold R., Baudin E., Cwikla J.B., Eriksson B., Fanti S., Fazio N., Giammarile F., Hicks R.J., Kjaer A., Krenning E., Kwekkeboom D., Lombard-Bohas C., O'Connor J.M., O'Toole D., Rockall A., Wiedenmann B., Valle J.W., and Vullierme M.-P.** ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging. [2017] *Neuroendocrinology* (105) 3 : 212-244. Impact factor : 5.024
- Sznol M., Postow M.A., Davies M.J., Pavlick A.C., Plimack E.R., Shaheen M., Veloski C., and Robert C.** Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. [2017] *Cancer Treatment Reviews* (58) : 70-76. Impact factor : 8.122
- Tahara M., Schlumberger M., Elisei R., Habra M.A., Kiyota N., Paschke R., Dutcus C.E., Hihara T., McGrath S., Matijevec M., Kadowaki T., Funahashi Y., and Sherman S.I.** Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. [2017] *European Journal of Cancer* (75) : 213-221. Impact factor : 7.191
- Talhaoui I., Matkarimov B.T., Tchenio T., Zharkov D.O., and Saparbaev M.K.** Aberrant base excision repair pathway of oxidatively damaged DNA: Implications for degenerative diseases. [2017] *Free radical biology & medicine* (107) : 266-277. Impact factor : 6.020
- Tao Y., Auperin A., Sire C., Martin M., Saliou M.G., Bardet E., Sun X.S., Chatellier T., Morand C., Cornely A., Angokai M., Di Rito A., Kichenin K., Blanchard P., D'Onofrio I., and Bourhis J.** Multicenter randomized double-blind, placebo-controlled trial GORTEC 2009-01 evaluating the effect of the regenerating agent RGTA on radiodermatitis of head and neck cancer patients. [2017] *International Journal of Radiation Oncology Biology Physics* (99) 3 : 590-595. Impact factor : 5.554
- Taylor N.J., Mitra N., Goldstein A.M., Tucker M.A., Avril M.F., Azizi E., Bergman W., Bishop D.T., Bressac de Paillerets B., Bruno W., Calista D., Cannon-Albright L.A., Cuellar F., Cust A.E., Demenais F., Elder D.E., Gerdes A.M., Ghiorzo P., Grazziotin T.C., Hansson J., Harland M., Hayward N.K., Hovevar M., Hoiom V., Ingvar C., Landi M.T., Landman G., Larre-Borges A., Leachman S.A., Mann G.J., Nagore E., Olsson H., Palmer J.M., Peric B., Pjanova D., Pritchard A., Puig S., van der Stoep N., Wadt K.A.W., Whitaker L., Yang X.R., Newton Bishop J.A., Gruis N.A., and Kanetsky P.A.** Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families. [2017] *Journal of Investigative Dermatology* (137) 2 : 2606-2612. Impact factor : 6.448
- Terroir M., Borget I., Bidault F., Ricard M., Deschamps F., Hartl D., Tselikas L., Dercle L., Lumbroso J., Baudin E., Berdelou A., Deandres D., Schlumberger M., and Leboulleux S.** The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer. [2017] *European Journal of Nuclear Medicine and Molecular Imaging* (44) 4 : 638-646. Impact factor : 7.704
- Terry S., Savagner P., Ortiz-Cuaran S., Mahjoubi L., Saintigny P., Thierry J.P., and Chouaib S.** New insights into the role of EMT in tumor immune escape. [2017] *Molecular Oncology* (11) 7 : 824-846. Impact factor : 5.264
- Terry S., Buart S., Tan T.Z., Gros G., Noman M.Z., Lorens J.B., Mami-Chouaib F., Thierry J.P., and Chouaib S.** Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity. [2017] *Oncolmmunology* (6) 2 : e1271858. Impact factor : 5.503
- Terry S., Buart S., and Chouaib S.** Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity. [2017] *Frontiers in Immunology* (8) : 1625. Impact factor : 5.511
- Thariat J., Sio T., Blanchard P., Patel S., Demizu Y., Ampil F., Guihard S., Miller R.C., Karlsson U., Krenqli M., Giap H., and Nguyen N.** Using Proton Beam Therapy in the Elderly Population: A Snapshot of Current Perception and Practice. [2017] *International Journal of Radiation Oncology Biology Physics* (98) 4 : 840-842. Impact factor : 5.554
- Tromme I., Legrand C., Devleeschauwer B., Leiter U., Suciú S., Eggermont A., Sacre L., Baurain J.F., Thomas L., Beutels P., and Speybroeck N.** Corrigendum to «Cost-effectiveness analysis in melanoma detection: A transition model applied to dermoscopy» [Eur J Cancer 67 (2016) 38-45]. [2017] *European Journal of Cancer* (82) : 247. Impact factor : 7.191
- Tselikas L., Bayle A., Malka D., Hollebecque A., Le Cesne A., Coriat R., and Mir O.** When Imaging Becomes Clinically Relevant: Multikinase Inhibitor-related Pancreatic Insufficiency and Pancreatic Atrophy. [2017] *Radiology* (282) 2 : 609-610. Impact factor : 7.469
- Ugurel S., Rohmel J., Ascierto P.A., Flaherty K.T., Grob J.J., Hauschild A., Larkin J., Long G.V., Lorigan P., McArthur G.A., Ribas A., Robert C., Schadendorf D., and Garbe C.** Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. [2017] *European Journal of Cancer* (83) : 247-257. Impact factor : 7.191
- Ussi A.E., Rebolj M., Thorat M.A., Bietrix F., Fauvel A.C., Hajdich M., Hill C., Walker I., van Engeland M., Cuzick J., and Meijer G.** Assessing opportunities for coordinated R&D in early cancer detection and management in Europe. [2017] *International Journal of Cancer* (140) 7 : 1700-1701. Impact factor : 7.360
- Vanpouille-Box C., Lhuillier C., Bezu L., Aranda F., Yamazaki T., Kepp O., Fucikova J., Spisek R., Demaria S., Formenti S.C., Zitvogel L., Kroemer G., and Galluzzi L.** Trial watch: Immune checkpoint blockers for cancer therapy. [2017] *Oncolmmunology* (6) 11 : e1373237. Impact factor : 5.503
- Vassal G., Kearns P., Blanc P., Scobie N., Heenen D., and Pearson A.** Orphan Drug Regulation: A missed opportunity for children and adolescents with cancer. [2017] *European Journal of Cancer* (84) : 149-158. Impact factor : 7.191
- Vaz-Luis I., O'Neill A., Sepucha K., Miller K.D., Baker E., Dang C.T., Northfelt D.W., Winer E.P., Sledge G.W., Schneider B., and Partridge A.H.** Survival Benefit Needed to Undergo Chemotherapy: Patient and Physician Preferences. [2017] *Cancer* (123) 15 : 2821-2828. Impact factor : 6.537
- Vaz-Luis I., Lin N.U., Keating N.L., Barry W.T., Winer E.P., and Freedman R.A.** Factors associated with early mortality among patients with De Novo metastatic breast cancer: A population-based study. [2017] *Oncologist* (22) 4 : 386-393. Impact factor : 5.306
- Verlingue L., Hollebecque A., Boige V., Ducreux M., Malka D., and Ferte C.** Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract

cancers an ideal playground? [2017] *European Journal of Cancer* (81) : 161-173. Impact factor : 7.191

Verlingue L., Malka D., Allorant A., Massard C., Ferte C., Lacroix L., Rouleau E., Auger N., Ngo M., Nicotra C., de Baere T., Tselikas L., Ba B., Michiels S., Scoazec J.Y., Boige V., Ducreux M., Soria J.C., and Hollebecque A. Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. [2017] *European Journal of Cancer* (87) : 122-130. Impact factor : 7.191

Voon D.C., Huang R.Y., Jackson R.A., and Thiery J.P. The EMT spectrum and therapeutic opportunities. [2017] *Molecular Oncology* (11) 7 : 878-891. Impact factor : 5.264

Walter T., Tougeron D., Baudin E., Le Malicot K., Lecomte T., Malka D., Hentic O., Manfredi S., Bonnet I., Guimbaud R., Coriat R., Lepere C., Desauw C., Thiriot-Bidault A., Dahan L., Roquin G., Aparicio T., Legoux J.L., Lombard-Bohas C., Scoazec J.Y., Lepage C., Cadiot G., Stephanie L., Borbath I., Castex, Petorin C., Terrebonne E., Bouhier-Leporrier K., Suc E., Hautefeuille V., Bourgeois V., Cany L., Dewaele F., Niccoli P., Seitz J.F., Lecaillon C., Rebischung C., Rossi V., Baconnier M., Dubreuil O., Ferec M., Deplanque G., Geslin G., Wanicki Caron I., Lavau Denes S., Bedenne L., Ligeza C., Maringe E., Ran-Royo A.L., Guigay J., and Rougier P. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort. [2017] *European Journal of Cancer* (79) : 158-165. Impact factor : 7.191

Wu Q., Allouch A., Martins I., Brenner C., Modjtahedi N., Deutsch E., and Perfettini J.L. Modulating Both Tumor Cell Death and Innate Immunity Is Essential for Improving Radiation Therapy Effectiveness. [2017] *Frontiers in Immunology* (8) : 613. Impact factor : 5.511

Wu Q., Allouch A., Paoletti A., Leteur C., Mirjolet C., Martins I., Voisin L., Law F., Dakhli H., Mintet E., Thoreau M., Muradova Z., Gauthier M., Caron O., Milliat F., Ojcius D.M., Rosselli F., Solary E., Modjtahedi N., Deutsch E., and Perfettini J.L. NOX2-dependent ATM kinase activation dictates pro-inflammatory macrophage phenotype and improves effectiveness to radiation therapy. [2017] *Cell Death and Differentiation* (24) 9 : 1632-1644. Impact factor : 8.000

Xie Y., Zhu S., Song X., Sun X., Fan Y., Liu J., Zhong M., Yuan H., Zhang L., Billiar T.R., Lotze M.T., Zeh H.J., III, Kang R., Kroemer G., and Tang D. The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity. [2017] *Cell Reports* (20) 7 : 1692-1704. Impact factor : 8.032

Zamora-Ros R., Barupal D., Rothwell J.A., Jenab M., Fedirko V., Romieu I., Aleksandrova K., Overvad K., Kyro C., Tjonneland A., Affret A., His M., Boutron-Ruault M.C., Katzke V., Kuhn T., Boeing H., Trichopoulou A., Naska A., Kritikou M., Saieva C., Agnoli C., Santucci de Magistris M., Tumino R., Fasanelli F., Weiderpass E., Skeie G., Merino S., Jakszyn P., Sanchez M.J., Dorronsoro M., Navarro C., Ardanaz E., Sonestedt E., Ericson U., Nilsson L.M., Boden S., Bueno-de-Mesquita H.B., Peeters P.H., Perez-Cornago A., Wareham N.J., Khaw K.T., Freisling H., Cross A.J., Riboli E., and Scalbert A. Dietary Flavonoid Intake and Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Cohort. [2017] *International Journal of Cancer* (140) 8 : 1836-1844. Impact factor : 7.360

Zheng J.S., Sharp S.J., Imamura F., Koulman A., Schulze M.B., Ye Z., Griffin J., Guevara M., Huerta J.M., Kroger J., Sluijs I., Agudo A., Barricarte A., Boeing H., Colorado-Yohar S., Dow C., Dorronsoro M., Dinesen P.T., Fagherazzi G., Franks P.W., Feskens E.J.M., Kuhn T., Katzke V.A., Key T.J., Khaw K.T., de Magistris M.S., Mancini F.R., Molina-Portillo E., Nilsson P.M., Olsen A., Overvad K., Palli D., Quiros J.R., Rolandsson O., Ricceri F., Spijkerman A.M.W., Slimani N., Tagliabue G., Tjonneland A., Tumino R., van der Schouw Y.T., Langenberg C., Riboli E., Forouhi N.G., and Wareham N.J. Association between plasma phospholipid saturated fatty acids and metabolic markers of lipid, hepatic, inflammation and glycaemic pathways in eight European countries: a cross-sectional analysis in the EPIC-InterAct study. [2017] *Bmc Medicine* (15) 1 : 203. Impact factor : 9.088

Zhou X., Xie L., Xia L., Bergmann F., Buchler M.W., Kroemer G., Hackert T., and Fortunato F. RIP3 attenuates the pancreatic damage induced by deletion of ATG7. [2017] *Cell Death and Disease* (8) 7 : e2918. Impact factor : 5.638